Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/28—Neurological disorders
  • G01N2800/2814—Dementia; Cognitive disorders

Definitions

• Neurodegenerative diseases are debilitating disorders of the nervous system that affect approximately 30 million individuals worldwide. Neurodegenerative diseases are challenging to treat and are also a growing health concern, both in terms of mortality and the cost of care for the afflicted.
• the nervous system is a fragile element of the body and has a limited capacity to regenerate from both acute injuries, such as stroke and spinal cord injury, or degenerative diseases.
• Neurodegenerative diseases can be characterized by progressive loss of neuronal subtypes in the brain and spinal cord and may be either sporadic or familial. Symptoms of neurodegenerative diseases commonly appear during middle or old age. Given the increasing life expectancy of the population, the incidence of these diseases will increase. New therapies are needed to treat neurodegenerative diseases.
• Frontotemporal dementia is a neurodegenerative disorder characterized by progressive deficits in either behavior and personality changes or language disturbance.
• FTD is an umbrella term for a broad spectrum of diseases including Progressive Supranuclear Palsy, Corticobasal Degeneration, and Amyotrophic Lateral Sclerosis (ALS).
• FTD is often misdiagnosed in the early stage, either as a psychiatric disorder, or as a different type of dementia such as Alzheimer's disease (AD). Because of the close similarity of behavioral changes in patients with frontotemporal dementia to those seen in patients with psychiatric disorders, diagnosis is challenging.
• Various underlying neuropathological changes lead to the FTD phenotype, all of which are characterized by selective degradation of the frontal and temporal cortices.
• FTD is commonly used for the description of a group of early onset dementias, and is the second most common dementing disorder among people under 65 years of age. However, in 25% of the cases FTD presents in old age. The estimated prevalence of FTD is 15- 22/100,000 and population studies indicate an equal gender distribution. The World Health Organization estimates that dementia rates will double nearly every 20 years, reaching an estimated 135.5 million people in 2050.
• Treatment is focused on management of behavioral symptoms. Severity of compulsion, agitation, aggressiveness, impulsivity, and aberrant eating behavior can improve with the use of selective serotonin reuptake inhibitors. Behavioral abnormalities can be managed with low doses of atypical antipsychotics. Cholinesterase inhibitors are not beneficial and can worsen behavioral abnormalities seen in patients with FTD. Memantine does not improve or delay progression of FTD symptoms.
• the present disclosure is generally directed to methods of preventing, reducing risk of developing, or treating frontotemporal dementia (FTD) or a variant of FTD, comprising administering to a subject an inhibitor of the complement pathway.
• FTD frontotemporal dementia
• synapse loss is of crucial importance to understanding the primary mechanisms of overall neurodegeneration.
• AD Alzheimer's Disease
• synapse loss is inhibited by contacting neurons with inhibitors or antagonists of the complement pathway.
• inhibitors may block activation of the complement cascade, can block the expression of specific complement proteins in neurons, interfere with signaling molecules that induce complement activation, upregulate expression of complement inhibitors in neurons, or otherwise interfere with the role of complement in synapse loss.
• the ability to prevent synapse loss e.g. in adult brains, has important implications for maintaining normal neuronal function in a variety of neurodegenerative conditions.
• inhibition of complement activation pathways may be a promising therapeutic strategy for preventing, reducing risk of developing, or treating frontotemporal dementia, e.g., using antibodies to inhibit the early stages of complement activation, including the complement activation pathway.
• anti-Clq, anti-Clr, and anti-Cls antibodies may prevent autoantibodies from triggering the classical pathway of complement activation and prevent synapse loss resulting from the neuronal expression of complement factors.
• the present disclosure is generally directed to methods of preventing, reducing risk of developing, or treating frontotemporal dementia (FTD) by inhibiting complement activation, e.g., by inhibiting complement factor Clq, Clr, or Cls, e.g., through the administration of antibodies, such as monoclonal, chimeric, humanized antibodies, antibody fragments, etc., which bind to one or more of these complement factors.
• FTD frontotemporal dementia
• Complement was originally defined as the heat-labile component of plasma that "complemented" the humoral system and aided antibody-dependent killing of bacteria.
• Complement is now known to be a tightly regulated proteolytic network of more than 30 proteins circulating in the blood or attached to membrane surfaces that coordinate crucial roles in mammalian innate immunity, especially as it relates to inflammation and the body's defense against invading organisms.
• Complement proteins are produced by many cell types and have diverse cooperative functions. For example, complement is involved in the clearance of self-antigens and apoptotic cells, forms a bridge to adaptive immunity, and also plays a significant role in tissue regeneration and tumor growth.
• the complement system relies on an interplay of soluble and cell-surface-bound proteins that interact with pathogen cell surfaces to mark them for destruction by phagocytes.
• the complement system is made up of a large number of distinct plasma proteins, primarily produced by the liver. A number of these proteins are a class of proteases known as zymogens, which are themselves activated by proteolytic cleavage. These zymogens may be widely distributed in an inactive form until an invading pathogen is detected.
• Complement activation is initiated through three pathways: classical, alternative and lectin pathways. All three pathways are initiated by detection of surface structures by pattern recognition proteins. In addition, all three pathways merge through a common intersection, complement C3.
• C3 is an acute phase reactant. The liver is the main site of synthesis, although small amounts are also produced by activated monocytes and macrophages.
• a single chain precursor (pro-C3) of approximately 200 kD is found intracellularly; the cDNA shows that it comprises 1,663 amino acids. This is processed by proteolytic cleavage into alpha and beta subunits, which in the mature protein are linked by disulfide bonds.
• Pro-C3 contains a signal peptide of 22 amino acid residues, the beta chain (645 residues) and the alpha chain (992 residues). The 2 chains are joined by 4 arginine residues that are not present in the mature protein.
• the classical pathway is activated by the binding of the complement protein Clq directly to patches of surface-bound antibodies (IgM and IgG), and also to C-reactive protein, serum amyloid P, pentraxin 3, and other known and unknown binding sites on the surfaces of cells, synapses, and microbes.
• IgM and IgG surface-bound antibodies
• C-reactive protein serum amyloid P, pentraxin 3, and other known and unknown binding sites on the surfaces of cells, synapses, and microbes.
• Clq is a large multimeric protein of 460 kDa consisting of 18 polypeptide chains (6 Clq A chains, 6 Clq B chains, and 6 Clq C chains).
• Clr and Cls complement proteins bind to the Clq tail region to form the CI complex (Clqr 2 S2). Binding of the Clq complex to the surface of a cell or to the complement binding domain of an antibody Fc region induces a conformational change in Clq that leads to activation of an autocatalytic enzymatic activity in Clr, which then cleaves Cls to generate an active serine protease. Once activated, Cls cleaves C4 resulting in C4b, which in turn binds to C2.
• C2 is cleaved by Cls, resulting in the activated form, C2a, bound to C4b and forming the C3 convertase (C4b2a) of the classical pathway.
• this pathway leads to the formation of a membrane attack complex, which lyses and kills the affected cell.
• the lectin pathway is activated by the binding of mannose-binding lectin (MBL) through two serum serine proteases designated MASP-1 and MASP-2. Similar to the classical complement pathway, the lectin complement pathway also requires C4 and C2 for activation of C3 and other terminal components further downstream in the cascade.
• MBL mannose-binding lectin
• complement pathway Activation of the complement pathway generates biologically active fragments of complement proteins, e.g., C3a, C4a and C5a anaphylatoxins and sC5b-9 membrane attack complex (MAC), which mediates inflammatory activities involving leukocyte chemotaxis, activation of macrophages, neutrophils, platelets, mast cells and endothelial cells, increased vascular permeability, cytolysis, and tissue injury.
• MAC membrane attack complex
• Antibody bound to a cell surface antigen can also activate the complement system, creating pores in the membrane of a foreign cell, or it can mediate cell destruction by antibody-dependent cell-mediated cytotoxicity (ADCC). In this process, cytotoxic cells with Fc receptors bind to the Fc region of antibodies on target cells and promote killing of the cells.
• ADCC antibody-dependent cell-mediated cytotoxicity
• Antibody bound to a foreign cell also can serve as an opsonin, enabling phagocytic cells with Fc or C3b receptors to bind and phagocytose the antibody-coated cell.
• Complement is nonspecific in that it can attack both foreign invaders and host cells.
• host cells including neurons, are protected from potential complement-mediated damage by various fluid-phase and membrane-bound complement regulatory proteins, such as CI inhibitor (Cl-Inh).
• Cl-INH dissociates Clr and Cls from the active CI complex, which protects host cells from lysis or damage from the membrane attack complex.
• C4BP C4b-binding protein
• FH factor H
• CR1 complement receptor 1
• CIg complement receptor Ig
• DAF decay accelerating factor
• MCP membrane cofactor protein
• complement components are expressed by neurons and glial cells in vitro and in vivo. While their function in the brain is unknown, the expression of many of these complement proteins is upregulated by serum or inflammatory cytokines after brain injury or during the course of neurodegenerative disease pathology. Astrocytes in culture have been reported to express Clq, Clr, Cls, C4, C2, and C3, as well as the more terminal complement proteins. Neurons have been reported to express C4 and C3. Clq was shown to be expressed in neuronal synapses and to mark these synapses for elimination. See, e.g., U.S. Patent Publication Nos. 2012/0195880 and 2012/328601.
• synapse loss While selective synapse loss is an essential aspect of normal brain development (“synaptic pruning"), excessive synapse loss, especially in a mature or aging brain, results in neurodegeneration and cognitive decline. Elevated synaptic complement expression led to contribute to synaptic loss in normal aging and in neurodegenerative disease progression. Conversely, lowering complement expression was neuroprotective. Neurons affected by synapse loss may be central nervous system neurons, or peripheral nervous system neurons.
• Neutralizing the activity of complement factors such as Clq, Clr, or Cls can block complement activity, prevent synapse loss, and slow neurodegenerative disease progression in disorders like FTD. Methods related to neutralizing complement factors such as Clq, Clr, or Cls in FTD are disclosed herein.
• a method of preventing, reducing risk of developing, or treating frontotemporal dementia (FTD) or a variant of FTD comprising administering to a subject an inhibitor of the complement pathway.
• FTD frontotemporal dementia
• a variant of FTD may include a behavioral variant, a semantic variant, a non-fluent variant, and/or primary progressive aphasia.
• the subject may have social symptoms, emotional symptoms, eating and oral symptoms, repetitive or compulsive symptoms, sensory symptoms, motor symptoms, executive symptoms, language symptoms, neuropsychiatric symptoms, and/or other symptoms.
• Disclosed herein is a method of inhibiting synapse loss in FTD, comprising administering to a patient suffering from adverse synapse loss an antibody, such as an anti- Clq antibody, an anti-Clr antibody, or an anti-Cls antibody.
• the method may further comprise administration of neural progenitors, or a neurogenesis enhancer.
• the antibody binds to Clq, Clr, or Cls and inhibits complement activation.
• Full-length antibodies may be prepared by the use of recombinant DNA engineering techniques.
• engineered versions include those created, for example, from natural antibody variable regions by insertions, deletions or changes in or to the amino acid sequences of the natural antibodies.
• Particular examples of this type include those engineered variable region domains containing at least one CDR and optionally one or more framework amino acids from one antibody and the remainder of the variable region domain from a second antibody.
• the DNA encoding the antibody may be prepared by deleting all but the desired portion of the DNA that encodes the full length antibody.
• DNA encoding chimerized antibodies may be prepared by recombining DNA substantially or exclusively encoding human constant regions and DNA encoding variable regions derived substantially or exclusively from the sequence of the variable region of a mammal other than a human.
• DNA encoding humanized antibodies may be prepared by recombining DNA encoding constant regions and variable regions other than the complementarity determining regions (CDRs) derived substantially or exclusively from the corresponding human antibody regions and DNA encoding CDRs derived substantially or exclusively from a mammal other than a human.
• CDRs complementarity determining regions
• Suitable sources of DNA molecules that encode antibodies include cells, such as hybridomas, that express the full length antibody.
• the antibody may be isolated from a host cell that expresses an expression vector that encodes the heavy and/or light chain of the antibody.
• Antibody fragments may also be prepared by the use of recombinant DNA
• PCR is used to generate an antibody fragment by introducing a stop codon immediately following the codon encoding the interchain cysteine of CHI, such that translation of the CHI domain stops at the interchain cysteine.
• stop codons may be introduced using site-directed mutagenesis techniques.
• An antibody of the present disclosure may be derived from any antibody isotype ("class") including for example IgG, IgM, IgA, IgD and IgE and subclasses thereof, including for example IgGl, IgG2, IgG3 and IgG4.
• the heavy and light chains of the antibody are from murine IgGl .
• the inhibitor is an antibody, such as an anti-Clq antibody, an anti-Clr antibody, or an anti-Cls antibody.
• the anti-Clq antibody may inhibit the interaction between Clq and an autoantibody, or between Clq and Clr, or between Clq and Cls.
• the anti-Clr antibody may inhibit the interaction between Clr and Clq, or between Clr and Cls.
• the anti-Clr antibody may inhibit the catalytic activity of Clr, or the anti-Clr antibody may inhibit the processing of pro-Clr to an active protease.
• the anti-Cls antibody may inhibit the interaction between Cls and Clq, or between Cls and Clr, or between Cls and C2 or C4, or the anti-Cls antibody may inhibit the catalytic activity of Cls, or it may inhibit the processing of pro-Cls to an active protease.
• the anti-Clq, anti-Clr, or anti-Cls antibody causes clearance of Clq, Clr or Cls from the circulation or a tissue.
• the antibody disclosed herein may be a monoclonal antibody, e.g., that binds mammalian Clq, Clr, or Cls, preferably human Clq, Clr, or Cls.
• the antibody may be a mouse antibody, a human antibody, a humanized antibody, a chimeric antibody, or an antibody fragment.
• the antibodies disclosed herein may also cross the blood brain barrier (BBB).
• BBB blood brain barrier
• the antibody may activate a BBB receptor-mediated transport system, such as a system that utilizes the insulin receptor, transferrin receptor, leptin receptor, LDL receptor, or IGF receptor.
• the antibody can be a chimeric antibody with sufficient human sequence that is suitable for administration to a human.
• the antibody can be glycosylated or nonglycosylated; in some embodiments, the antibody is glycosylated, e.g., in a glycosylation pattern produced by post-translational modification in a CHO cell.
• the antibodies of the present disclosure may also be covalently linked to a therapeutic agent, such as an anti-inflammatory protein, neurotherapeutic agent, anti-viral, anti-parasitic, anti -bacterial, endocrine drug, metabolic drug, mitotoxin, chemotherapy drug, or siRNA, for which transport across the BBB is desired.
• a therapeutic agent such as an anti-inflammatory protein, neurotherapeutic agent, anti-viral, anti-parasitic, anti -bacterial, endocrine drug, metabolic drug, mitotoxin, chemotherapy drug, or siRNA, for which transport across the BBB is desired.
• the covalent linkage between the antibody and, for example, the neurotherapeutic agent may be a linkage between any suitable portion of the antibody and the therapeutic agent, as long as it allows the antibody-agent fusion to cross the blood brain barrier and the therapeutic agent to retain a therapeutically useful portion of its activity within the central nervous system.
• the covalent link may be between one or more light chains of the antibody and the therapeutic agent.
• a peptide neurotherapeutic agent e.g., a neurotrophin such as brain derived neurotrophic factor, BDNF
• the peptide can be covalently linked by its carboxy or amino terminus to the carboxy or amino terminus of the light chain (LC) or heavy chain (HC) of the antibody.
• neurotherapeutic agents that can be linked to antibodies of the present disclosure include a neurotrophin selected from brain derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-4/5, fibroblast growth factor (FGF)-2 and other FGFs, neurotrophin (NT)-3, erythropoietin (EPO), hepatocyte growth factor (HGF), epidermal growth factor (EGF), transforming growth factor (TGF)-a, TGF- ⁇ , vascular endothelial growth factor (VEGF), interleukin-1 receptor antagonist (IL-lra), ciliary neurotrophic factor (CNTF), glial-derived neurotrophic factor (GDNF), neurturin, platelet- derived growth factor (PDGF), heregulin, neuregulin, artemin, persephin, interleukins, granulocyte-colony stimulating factor (CSF), granulocyte-macrophage-CSF, netrins, cardiotrophin-1, hedgehogs, leukemia
• the antibody may be a bispecific antibody, recognizing a first and a second antigen, e.g., the first antigen is selected from Clq, Clr, and Cl s and/or the second antigen is an antigen that allows the antibody to cross the blood-brain-barrier, such as an antigen selected from transferrin receptor (TR), insulin receptor (HTR), Insulin-like growth factor receptor (IGFR), low-density lipoprotein receptor related proteins 1 and 2 (LPR-1 and 2), diphtheria toxin receptor, CRM197, a llama single domain antibody, TMEM 30(A), a protein transduction domain, TAT, Syn-B, penetratin, a poly-arginine peptide, an angiopep peptide, or ANG1005.
• TR transferrin receptor
• HTR insulin receptor
• IGFR Insulin-like growth factor receptor
• LPR-1 and 2 low-density lipoprotein receptor related proteins 1 and 2
• CRM197 a llama single domain
• An antibody of the present disclosure may bind to and inhibit a biological activity of Clq, Clr, or CI .
• Clq binding to an autoantibody (2) Clq binding to Clr, (3) Clq binding to CI s, (4) Clq binding to phosphatidylserine, (5) Clq binding to pentraxin- 3, (6) Clq binding to C-reactive protein (CRP), (7) Clq binding to globular Clq receptor (gClqR), (8) Clq binding to complement receptor 1 (CR1), (9) Clq binding to B-amyloid, or (10) Clq binding to calreticulin.
• CRP C-reactive protein
• gClqR globular Clq receptor
• CR1 complement receptor 1
• B-amyloid or (10) Clq binding to calreticulin.
• the biological activity of Clq is (1) activation of the classical complement activation pathway, (2) activation of antibody and complement dependent cytotoxicity, (3) CH50 hemolysis, (4) synapse loss, (5) B-cell antibody production, (6) dendritic cell maturation, (7) T-cell proliferation, (8) cytokine production (9) microglia activation, (10) Arthus reaction, (11) phagocytosis of synapses or nerve endings or (12) activation of complement receptor 3 (CR3/C3) expressing cells.
• CH50 hemolysis comprises human, mouse, and/or rat CH50 hemolysis.
• the antibody is capable of neutralizing from at least about 50%, to at least about 95% of CH50 hemolysis.
• the antibody may also be capable of neutralizing at least 50% of CH50 hemolysis at a dose of less than 150 ng, less than 100 ng, less than 50 ng, or less than 20 ng.
• in vitro assays to measure complement activity include ELISA assays for the measurement of split products of complement components or complexes that form during complement activation.
• Complement activation via the classical pathway can be measured by following the levels of C4d and C4 in the serum.
• Activation of the alternative pathway can be measured in an ELISA by assessing the levels of Bb or C3bBbP complexes in circulation.
• An in vitro antibody-mediated complement activation assay may also be used to evaluate inhibition of C3a production.
• An antibody of the present disclosure may be a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a humanized antibody, a chimeric antibody, a
• the antibodies of the present disclosure may also be an antibody fragment, such as a Fab fragment, a Fab' fragment, a F(ab') 2 fragment, a Fv fragment, a diabody, or a single chain antibody molecule.
• a second agent such as a second antibody or a second inhibitor.
• the antibody may be an anti-Clq antibody, an anti-Clr antibody, or an anti-Cls antibody.
• the inhibitor may be an inhibitor of antibody- dependent cellular cytotoxicity, alternative complement activation pathway; and/or an inhibitor of the interaction between the autoantibody and an autoantigen.
• a method is provided of determining a subject's risk of developing frontotemporal dementia, comprising: (a) administering an antibody to the subject (i.e. an anti-Clq, anti-Clr, or anti-Cls antibody) , wherein the antibody is coupled to a detectable label; (b) detecting the detectable label to measure the amount or location of Clq, Clr, or Cls in the subject; and (c) comparing the amount or location of one or more of Clq, Clr, or Cls to a reference, wherein the risk of developing frontotemporal dementia is characterized based on a the comparison of the amount or location of one or more of Clq, Clr, or Cls to the reference.
• the detectable label may comprise a nucleic acid
• the antibody may be labeled with a coenzyme such as biotin using the process of
• biotinylation When biotin is used as a label, the detection of the antibody is accomplished by addition of a protein such as avidin or its bacterial counterpart streptavidin, either of which can be bound to a detectable marker such as the aforementioned dye, a fluorescent marker such as fluorescein, a radioactive isotope or an enzyme such as peroxidase.
• the antibody is an antibody fragment (e.g., Fab, Fab'-SH, Fv, scFv, or F(ab') 2 fragments).
• the antibodies disclosed herein may also be coupled to a labeling group, e.g., an radioisotope, radionuclide, an enzymatic group, biotinyl group, a nucleic acid,
• a labeling group e.g., an radioisotope, radionuclide, an enzymatic group, biotinyl group, a nucleic acid
• a labeling group may be coupled to the antibody via a spacer arm of any suitable length to reduce potential steric hindrance.
• spacer arm of any suitable length to reduce potential steric hindrance.
• Various methods for labeling proteins are known in the art and can be used to prepare such labeled antibodies.
• Such routes of administration include but are not limited to, topical, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intrathecal, intranasal, and intralesional administration.
• Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous
• the antibody may be adapted to cross the blood-brain barrier following a non-invasive peripheral route of administration such as intravenous intramuscular, subcutaneous, intraperitoneal, or even oral administration.
• the present disclosure also provides a method of detecting synapses in an individual, by a) administering an antibody from any of the embodiments to the subject, wherein the antibody is coupled to a detectable label; (b) detecting the detectable label to measure the amount or location of the antibody in the subject; and (c) comparing the amount or location of the antibody to a reference, wherein the risk of developing a disease associated with complement activation is characterized based on the comparison of the amount of antibody as compared to the reference.
• the detectable label may comprise a nucleic acid, oligonucleotide, enzyme, radioactive isotope, biotin, or a fluorescent label (e.g., fluorescein, rhodamine, cyanine dyes or BODIPY).
• the detectable label may be detected using an imaging agent for x-ray, CT, MRI, ultrasound, PET and SPECT.
• Figure 1 depicts the amino acid sequence of Homo sapiens complement C l s protein (SEQ ID NO:70).
• Figure 2 depicts an amino acid sequence of humanized IPN003 VH variant 1 (SEQ ID NO.79); and a nucleotide sequence (SEQ ID NO: 86) encoding the amino acid sequence.
• Figure 3 depicts an amino acid sequence of humanized IPN003 VH variant 2 (SEQ ID NO.80); and a nucleotide sequence (SEQ ID NO: 87) encoding the amino acid sequence.
• Figure 4 depicts an amino acid sequence of humanized IPN003 VH variant 3 (SEQ ID NO.81); and a nucleotide sequence (SEQ ID NO: 88) encoding the amino acid sequence.
• Figure 5 depicts an amino acid sequence of humanized IPN003 VH variant 4 (SEQ ID NO.82); and a nucleotide sequence (SEQ ID NO: 89) encoding the amino acid sequence.
• Figure 6 depicts an amino acid sequence of humanized IPN003 VK variant 1 (SEQ ID NO.83); and a nucleotide sequence (SEQ ID NO: 90) encoding the amino acid sequence.
• Figure 7 depicts an amino acid sequence of humanized IPN003 VK variant 2 (SEQ ID NO.84); and a nucleotide sequence (SEQ ID NO: 91) encoding the amino acid sequence.
• Figure 8 depicts an amino acid sequence of humanized IPN003 VK variant 3 (SEQ ID NO.85); and a nucleotide sequence (SEQ ID NO: 92) encoding the amino acid sequence.
• Figure 9 provides Table 3, which shows the amino acid differences between parental IPN003 VH and exemplary VH variants; and Table 4, which shows the amino acid differences between parental IPN003 VL and exemplary VL variants.
• the present disclosure relates generally to methods of preventing, reducing risk of developing, or treating frontotemporal dementia (FTD) or a variant of FTD, comprising administering to a subject an inhibitor of the complement pathway.
• FTD frontotemporal dementia
• Suitable antibodies include antibodies that bind to complement component Clq, C lr, or C l s. Such antibodies include monoclonal antibodies and homologues, analogs, and modified or derived forms thereof, including Fab, F(ab') 2 , Fv and single chain antibodies.
• Preferred antibodies are monoclonal antibodies, which can be raised by immunizing rodents (e.g., mice, rats, hamsters and guinea pigs) with either (1) the native complement component (e.g., Clq, Clr, or C l s) derived from enzymatic digestion of a purified complement component from human plasma or serum, or (2) a recombinant complement component, or its derived fragment, expressed by either eukaryotic or prokaryotic systems.
• Other animals can be used for immunization, e.g., non-human primates, transgenic mice expressing human immunoglobulins, and severe combined immunodeficient (SCID) mice transplanted with human B-lymphocytes.
• SCID severe combined immunodeficient
• Ig immunoglobulin
• Hybridomas can be generated by conventional procedures by fusing B-lymphocytes from the immunized animals with myeloma cells.
• anti -Clq, -Clr, or -Cls antibodies can be generated by screening recombinant single-chain Fv or Fab libraries from human B-lymphocytes in a phage-display system.
• the specificity of the MAbs to human Clq, Clr, or Cls can be tested by enzyme linked immunosorbent assay (ELISA), Western immunoblotting, or other immunochemical techniques.
• the inhibitory activity on complement activation of antibodies identified in the screening process can be assessed by hemolytic assays using either unsensitized rabbit or guinea pig RBCs for the alternative complement pathway, or sensitized chicken or sheep RBCs for the classical complement pathway. Those hybridomas that exhibit an inhibitory activity specific for the classical complement pathway are cloned by limiting dilution. The antibodies are purified for characterization for specificity to human Clq, Clr, or Cls by the assays described above.
• molecular modeling and rational molecular design may be used to generate and screen small molecules that mimic the molecular structures of the binding region of the antibodies and inhibit the activities of Clq, Clr, or Cls.
• These small molecules can be peptides, peptidomimetics, oligonucleotides, or organic compounds.
• the mimicking molecules can be used as inhibitors of complement activation in inflammatory indications and autoimmune diseases. Alternatively, one can use large-scale screening procedures commonly used in the field to isolate suitable small molecules from libraries of combinatorial compounds.
• a suitable dosage of an antibody as disclosed herein may be between 10 and 500 ⁇ g/ml of serum.
• the actual dosage can be determined in clinical trials following the conventional methodology for determining optimal dosages, i.e., administering various dosages and determining which doses provide suitable efficacy without undesirable side- effects.
• proteolytic enzymes proteolytic enzymes that cleave polypeptide sequences were used to dissect the structure of antibody molecules and to determine which parts of the molecule are responsible for its various functions.
• Fab fragments Two fragments, known as Fab fragments, are identical and contain the antigen-binding activity.
• the Fab fragments correspond to the two identical arms of the antibody molecule, each of which consists of a complete light chain paired with the VH and CHI domains of a heavy chain.
• the other fragment contains no antigen binding activity but was originally observed to crystallize readily, and for this reason was named the Fc fragment (Fragment crystallizable).
• a Fab molecule is an artificial ⁇ 50-kDa fragment of the Ig molecule with a heavy chain lacking constant domains CH2 and CH3. TWO heterophilic (VL-VH and CL-CH1) domain interactions underlie the two-chain structure of the Fab molecule, which is further stabilized by a disulfide bridge between CL and CHI .
• Fab and IgG have identical antigen binding sites formed by six complementarity-determining regions (CDRs), three each from VL and VH (LCDR1, LCDR2, LCDR3 and HCDR1, HCDR2, HCDR3). The CDRs define the hypervariable antigen binding site of antibodies.
• LCDR3 and HCDR3 which in natural immune systems are generated by the rearrangement of VL and JL genes or VH, DH and JH genes, respectively.
• LCDR3 and HCDR3 typically form the core of the antigen binding site.
• the conserved regions that connect and display the six CDRs are referred to as framework regions.
• the framework regions form a sandwich of two opposing antiparallel ⁇ -sheets that are linked by hypervariable CDR loops on the outside and by a conserved disulfide bridge on the inside.
• Methods are disclosed herein for protecting or treating an individual suffering from adverse effects of synapse loss, such as in frontotemporal dementia. It is shown herein that immature astrocytes in normal development produce a signal that induces neurons to express a specific complement protein, thus enabling a developmental window during which synapse elimination occurs. Expression of such a protein in development mirrors the period of developmental synaptogenesis, being off in embryonic brain and adult brain but on at high levels in postnatal brain.
• synapse loss is inhibited by contacting neurons with inhibitors or antagonists of the complement pathway.
• inhibitors can block activation of the complement cascade, can block the expression of specific complement proteins in neurons, can interfere with signaling molecules that induce complement activation, can upregulate expression of complement inhibitors in neurons, and otherwise interfere with the role of complement in synapse loss.
• the ability to prevent synapse loss, e.g., in adult brains, has important implications for maintaining normal neuronal function in a variety of
• Suitable inhibitors include an antibody that binds complement Clq protein (i.e., an anti-complement Clq antibody, also referred to herein as an anti-Clq antibody and a Clq antibody) and a nucleic acid molecule that encodes such an antibody for a method of preventing, reducing risk of developing, or treating frontotemporal dementia.
• complement Clq protein i.e., an anti-complement Clq antibody, also referred to herein as an anti-Clq antibody and a Clq antibody
• nucleic acid molecule that encodes such an antibody for a method of preventing, reducing risk of developing, or treating frontotemporal dementia.
• the antibody may bind to at least human Clq, mouse Clq, or rat Clq.
• the antibody may be a humanized antibody, a chimeric antibody, or a human antibody.
• the light chain variable domain comprises the HVR-L1, HVR-L2, and HVR-L3 of the monoclonal antibody Ml produced by a hybridoma cell line deposited with Accession Number PTA-120399.
• the heavy chain variable domain comprises the HVR-Hl, HVR-H2, and HVR-H3 of the monoclonal antibody Ml produced by a hybridoma cell line deposited with ATCC Accession Number PTA-120399.
• the amino acid sequence of the light chain variable domain and heavy chain variable domain comprise one or more of SEQ ID NO:5 of HVR-L1, SEQ ID NO:6 of HVR-L2, SEQ ID NO:7 of HVR-L3, SEQ ID NO:9 of HVR-Hl, SEQ ID NO: 10 of HVR-H2, and SEQ ID NO: 11 of HVR-H3.
• the antibody may comprise a light chain variable domain amino acid sequence that is at least 85% identical to SEQ ID NO:4 and a heavy chain variable domain amino acid sequence that is at least 85% identical to SEQ ID NO:8.
• an anti-Clq antibody inhibits the interaction between Clq and an autoantibody.
• the anti-Clq antibody inhibits the interaction between Clq and the synapse.
• the anti- Clq antibody causes clearance of Clq from the circulation or tissue.
• the anti-Clq antibody may bind to a Clq protein, and binds to one or more amino acids of the Clq protein within amino acid residues selected from (a) amino acid residues 196-226 of SEQ ID NO: 1 (SEQ ID NO: 16), or amino acid residues of a Clq protein chain A (ClqA) corresponding to amino acid residues 196-226
• the antibody further binds to one or more amino acids of the
• Clq protein within amino acid residues selected from: (a) amino acid residues 218-240 of SEQ ID NO:3 (SEQ ID NO:20) or amino acid residues of a Clq protein chain C (ClqC) corresponding to amino acid residues 218-240 (WLAVNDYYDMVGI QGSDSVFSGF) of SEQ ID NO:3 (SEQ ID NO:20); (b) amino acid residues 225-240 of SEQ ID NO:3 (SEQ ID NO:21) or amino acid residues of a ClqC corresponding to amino acid residues 225-240
• the anti-Clq antibody binds to amino acid residue Lys 219 and Ser 202 of the human ClqA as shown in SEQ ID NO: 1 or amino acids of a human ClqA corresponding to Lys 219 and Ser 202 as shown in SEQ ID NO: 1, and amino acid residue Tyr 225 of the human ClqC as shown in SEQ ID NO: 3 or an amino acid residue of a human ClqC corresponding to Tyr 225 as shown in SEQ ID NO:3.
• the anti-Clq antibody binds to amino acid residue Lys 219 of the human ClqA as shown in SEQ ID NO: l or an amino acid residue of a human ClqA corresponding to Lys 219 as shown in SEQ ID NO: 1, and amino acid residue Ser 185 of the human ClqC as shown in SEQ ID NO:3 or an amino acid residue of a human ClqC corresponding to Ser 185 as shown in SEQ ID NO:3.
• the anti-Clq antibody binds to a Clq protein and binds to one or more amino acids of the Clq protein within amino acid residues selected from: (a) amino acid residues 218-240 of SEQ ID NO: 3 (SEQ ID NO:20) or amino acid residues of a ClqC corresponding to amino acid residues 218-240 (WLAVNDYYDMVGI QGSDSVFSGF) of SEQ ID NO:3 (SEQ ID NO:20); (b) amino acid residues 225-240 of SEQ ID NO:3 (SEQ ID NO:21) or amino acid residues of a ClqC corresponding to amino acid residues 225-240 (YDMVGI QGSDSVFSGF) of SEQ ID NO:3 (SEQ ID NO:21); (c) amino acid residues 225- 232 of SEQ ID NO:3 (SEQ ID NO:22) or amino acid residues of a ClqC corresponding to amino acid residues 225-232 (YDMVGIQG) of
• the anti-Clq antibody of this disclosure inhibits the interaction between Clq and Cls. In some embodiments, the anti-Clq antibody inhibits the interaction between Clq and Clr. In some embodiments the anti-Clq antibody inhibits the interaction between Clq and Cls and between Clq and Clr. In some embodiments, the anti-Clq antibody inhibits the interaction between Clq and another antibody, such as an autoantibody. In preferred embodiments, the anti-Clq antibody causes clearance of Clq from the circulation or tissue. In some embodiments, the anti-Clq antibody inhibits the respective interactions, at a stoichiometry of less than 2.5: 1; 2.0: 1; 1.5: 1; or 1.0: 1. In some
• the Clq antibody inhibits an interaction, such as the Clq-Cls interaction, at approximately equimolar concentrations of Clq and the anti-Clq antibody.
• the anti-Clq antibody binds to Clq with a stoichiometry of less than 20: 1; less than 19.5: 1; less thanl9: l; less than 18.5: 1; less than 18: 1; less than 17.5: 1; less than 17: 1; less than 16.5: 1; less than 16: 1; less than 15.5: 1; less than 15: 1 ; less than 14.5: 1; less than 14: 1; less than 13.5: 1; less than 13 : 1; less than 12.5: 1; less than 12: 1; less than 11.5: 1; less than 11 : 1; less than 10.5: 1; less than 10: 1; less than 9.5: 1; less than 9: 1; less than 8.5: 1; less than 8: 1; less than 7.5: 1; less than 7: 1; less than
• the anti-Clq antibody binds Clq with a binding stoichiometry that ranges from 20: 1 to 1.0: 1 or less thanl .0: 1. In certain embodiments, the anti-Clq antibody binds Clq with a binding stoichiometry that ranges from 6: 1 to 1.0: 1 or less thanl .0: l . In certain embodiments, the anti-Clq antibody binds Clq with a binding stoichiometry that ranges from 2.5: 1 to 1.0: 1 or less thanl .0: 1. In some
• the anti-Clq antibody inhibits the interaction between Clq and Clr, or between Clq and Cls, or between Clq and both Clr and Cls. In some embodiments, the anti-Clq antibody inhibits the interaction between Clq and Clr, between Clq and Cls, and/or between Clq and both Clr and Cls. In some embodiments, the anti-Clq antibody binds to the Clq A-chain. In other embodiments, the anti-Clq antibody binds to the Clq B- chain. In other embodiments, the anti-C lq antibody binds to the C lq C-chain.
• the anti-C lq antibody binds to the C lq A-chain, the C lq B-chain and/or the Clq C-chain. In some embodiments, the anti-C lq antibody binds to the globular domain of the Clq A-chain, B-chain, and/or C-chain. In other embodiments, the anti-Clq antibody binds to the collagen-like domain of the C lq A-chain, the Clq B-chain, and/or the C lq C- chain.
• the interaction occurring in the presence of the antibody may be reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%), at least 90%, at least 95%, or at least 99% relative to a control wherein the antibodies of this disclosure are absent.
• the interaction occurring in the presence of the antibody is reduced by an amount that ranges from at least 30% to at least 99% relative to a control wherein the antibodies of this disclosure are absent.
• the antibodies of this disclosure inhibit C2 or C4-cleavage by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%, or by an amount that ranges from at least 30% to at least 99%, relative to a control wherein the antibodies of this disclosure are absent.
• the ECso values for antibodies of this disclosure with respect C2 or C4-cleavage may be less than 3 ⁇ / ⁇ 1; 2.5 ⁇ g/ml; 2.0 ⁇ 1.5 ⁇ 1.0 ⁇ ; 0.5 ⁇ 0.25 ⁇ 0.1 ⁇ 0.05 ⁇ .
• the antibodies of this disclosure inhibit C2 or C4-cleavage at
• the antibodies of this disclosure inhibit autoantibody- dependent and complement-dependent cytotoxicity (CDC) by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%, or by an amount that ranges from at least 30% to at least 99%, relative to a control wherein the antibodies of this disclosure are absent.
• CDC autoantibody- dependent and complement-dependent cytotoxicity
• the ECso values for antibodies of this disclosure with respect to inhibition of autoantibody-dependent and complement- dependent cytotoxicity may be less than 3 ⁇ / ⁇ 1; 2.5 ⁇ / ⁇ 1; 2.0 ⁇ / ⁇ 1; 1.5 ⁇ / ⁇ 1; 1.0 ⁇ / ⁇ 1; 0.5 ⁇ g/ml; 0.25 ⁇ g/ml; 0.1 ⁇ g/ml; 0.05 ⁇ g/ml.
• the antibodies of this disclosure inhibit complement-dependent cell-mediated cytotoxicity (CDCC) by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%, or by an amount that ranges from at least 30% to at least 99%, relative to a control wherein the antibodies of this disclosure are absent.
• CDCC complement-dependent cell-mediated cytotoxicity
• the ECso values for antibodies of this disclosure with respect CDCC inhibition may be 1 less than 3 ⁇ g/ml; 2.5 ⁇ g/ml; 2.0 ⁇ g/ml; 1.5 ⁇ g/ml; 1.0 ⁇ g/ml; 0.5 ⁇ g/ml; 0.25 ⁇ g/ml; 0.1 ⁇ g/ml; 0.05 ⁇ g/ml.
• the antibodies of this disclosure inhibit CDCC but not antibody-dependent cellular cytotoxicity (ADCC).
• Humanized antibodies of the present disclosure specifically bind to a complement factor Clq and/or Clq protein in the CI complex of the classical complement pathway.
• the humanized anti-Clq antibody may specifically bind to human Clq, human and mouse Clq, to rat C 1 q, or human Clq, mouse Clq, and rat C 1 q.
• the human heavy chain constant region is a human IgG4 heavy chain constant region comprising the amino acid sequence of SEQ ID NO:47, or with at least 70%), at least about 75%, at least about 80%, at least about 85%, at least about 90% homology to SEQ ID NO: 37.
• the human IgG4 heavy chain constant region may comprise an Fc region with one or more modifications and/or amino acid substitutions according to Kabat numbering.
• the Fc region comprises a leucine to glutamate amino acid substitution at position 248, wherein such a substitution inhibits the Fc region from interacting with an Fc receptor.
• the Fc region comprises a serine to proline amino acid substitution at position 241, wherein such a substitution prevents arm switching in the antibody.
• the amino acid sequence of human IgG4 (S241P L248E) heavy chain constant domain is:
• the antibody may comprise a heavy chain variable domain and a light chain variable domain, wherein the heavy chain variable domain comprises an amino acid sequence selected from any one of SEQ ID NOs: 31-34, or an amino acid sequence with at least about 90% homology to the amino acid sequence selected from any one of SEQ ID NOs: 31-34.
• the light chain variable domain comprises an amino acid sequence selected from any one of SEQ ID NOs: 35-38, or an amino acid sequence with at least about 90% homology to the amino acid sequence selected from any one of SEQ ID NOs: 35-38.
• VH1 The amino acid sequence of heavy chain variable domain variant 1 (VH1) is:
• VH1 QVQLVQSGAELKKPGASVKVSCKSSGYHFTSYWMHWVKQAPGQGLEWIGVIHPN SGSINYNEKFESKATITVDKSTSTAYMQLSSLTSEDSAVYYCAGERDSTEVLPMDY WGQGTSVTVSS (SEQ ID NO: 31).
• the hyper variable regions (HVRs) of VH1 are depicted in bolded and underlined text.
• VH2 The amino acid sequence of heavy chain variable domain variant 2 (VH2) is:
• VH2 QVQLVQSGAELKKPGASVKVSCKSSGYHFTSYWMHWVKQAPGQGLEWIGVIHPN SGSINYNEKFESRATITVDKSTSTAYMELSSLRSEDTAVYYCAGERDSTEVLPMDY WGQGTTVTVSS (SEQ ID NO: 32).
• the hyper variable regions (HVRs) of VH2 are depicted in bolded and underlined text.
• VH3 The amino acid sequence of heavy chain variable domain variant 3 (VH3) is:
• VH4 The amino acid sequence of heavy chain variable domain variant 4 (VH4) is:
• VH4 QVQLVQSGAELKKPGASVKVSCKSSGYHFTSYWMHWVRQAPGQGLEWIGVIHPN SGSINYNEKFESRVTITVDKSTSTAYMELSSLRSEDTAVYYCAGERDSTEVLPMDY WGQGTTVTVSS (SEQ ID NO: 34).
• the hyper variable regions (HVRs) of VH4 are depicted in bolded and underlined text.
• VKI kappa light chain variable domain variant 1
• SEQ ID NO: 1 The amino acid sequence of kappa light chain variable domain variant 1 (VKI) is: DVQITQSPSYLAASLGERATINCRASKSINKYLAWYQQKPGKT KLLIYSGSTLOSGI PARFSGSGSGTDFTLTISSLEPEDFAMYYCOOHNEYPLTFGQGTKLEIK (SEQ ID NO:
• VK2 kappa light chain variable domain variant 2
• hyper variable regions (HVRs) of VK2 are depicted in bolded and underlined text.
• VK3 The amino acid sequence of kappa light chain variable domain variant 3 (VK3) is: DVOITOSPSSLSASLGERATINCRASKSINKYLAWYQQKPGKAPKLLIYSGSTLQSGI PARFSGSGSGTDFTLTISSLEPEDFAMYYCOOHNEYPLTFGQGTKLEIK (SEQ ID NO:
• hyper variable regions (HVRs) of VK3 are depicted in bolded and underlined text.
• VK4 The amino acid sequence of kappa light chain variable domain variant 4 (VK4) is: DIOLTOSPSSLSASLGERATINCRASKSINKYLAWYQQKPGKAPKLLIYSGSTLQSGIP ARFSGSGSGTDFTLTISSLEPEDFAMYYCOOHNEYPLTFGQGTKLEIK (SEQ ID NO:
• hyper variable regions (HVRs) of VK4 are depicted in bolded and underlined text.
• humanized anti-Clq antibodies of the present disclosure include a heavy chain variable region that contains an Fab region and a heavy chain constant regions that contains an Fc region, where the Fab region specifically binds to a Clq protein of the present disclosure, but the Fc region is incapable of binding the Clq protein.
• the Fc region is from a human IgGl, IgG2, IgG3, or IgG4 isotype.
• the Fc region is incapable of inducing complement activity and/or incapable of inducing antibody-dependent cellular cytotoxicity (ADCC).
• the Fc region comprises one or more modifications, including, without limitation, amino acid substitutions.
• the Fc region of humanized anti-Clq antibodies of the present disclosure comprise an amino acid substitution at position 248 according to Kabat numbering convention or a position corresponding to position 248 according to Kabat numbering convention, and/or at position 241 according to Kabat numbering convention or a position corresponding to position 241 according to Kabat numbering convention.
• the amino acid substitution at position 248 or a positions corresponding to position 248 inhibits the Fc region from interacting with an Fc receptor.
• the amino acid substitution at position 248 or a positions corresponding to position 248 is a leucine to glutamate amino acid substitution.
• the amino acid substitution at position 241 or a positions corresponding to position 241 prevents arm switching in the antibody. In some embodiments, the amino acid substitution at position 241 or a positions corresponding to position 241 is a serine to proline amino acid
• the Fc region of humanized anti-Clq antibodies of the present disclosure comprises the amino acid sequence of SEQ ID NO: 37, or an amino acid sequence with at least about 70%, at least about 75%, at least about 80% at least about 85% at least about 90%, or at least about 95% homology to the amino acid sequence of SEQ ID NO: 47.
• humanized anti-Clq antibodies of the present disclosure may bind to a Clq protein and binds to one or more amino acids of the Clq protein within amino acid residues selected from (a) amino acid residues 196-226 of SEQ ID NO: 39 (SEQ ID NO:42), or amino acid residues of a Clq protein chain A (ClqA) corresponding to amino acid residues 196-226 (GLFQVVSGGMVLQLQQGDQVWVEKDPKKGHI) of SEQ ID NO: 39 (SEQ ID NO:42); (b) amino acid residues 196-221 of SEQ ID NO: 39 (SEQ ID NO:43), or amino acid residues of a ClqA corresponding to amino acid residues 196-221
• the humanized anti-Clq antibodies may further binds to one or more amino acids of the Clq protein within amino acid residues selected from: (a) amino acid residues 218-240 of SEQ ID NO: 41 (SEQ ID NO:46) or amino acid residues of a Clq protein chain C (ClqC) corresponding to amino acid residues 218-240
• humanized anti-Clq antibodies of the present disclosure may bind to amino acid residue Lys 219 and Ser 202 of the human ClqA as shown in SEQ ID NO: 39 or amino acids of a human ClqA corresponding to Lys 219 and Ser 202 as shown in SEQ ID NO: 39, and amino acid residue Tyr 225 of the human ClqC as shown in SEQ ID NO: 41 or an amino acid residue of a human ClqC corresponding to Tyr 225 as shown in SEQ ID NO: 41.
• the anti-Clq antibody binds to amino acid residue Lys 219 of the human ClqA as shown in SEQ ID NO: 39 or an amino acid residue of a human ClqA corresponding to Lys 219 as shown in SEQ ID NO: 39, and amino acid residue Ser 185 of the human ClqC as shown in SEQ ID NO: 41 or an amino acid residue of a human ClqC corresponding to Ser 185 as shown in SEQ ID NO: 41.
• humanized anti-Clq antibodies of the present disclosure may bind to a Clq protein and binds to one or more amino acids of the Clq protein within amino acid residues selected from: (a) amino acid residues 218-240 of SEQ ID NO: 41 (SEQ ID NO:46) or amino acid residues of a ClqC corresponding to amino acid residues 218-240 (WLAVNDYYDMVGI QGSDSVFSGF) of SEQ ID NO: 41 (SEQ ID NO:46); (b) amino acid residues 225-240 of SEQ ID NO: 41 (SEQ ID NO:48) or amino acid residues of a ClqC corresponding to amino acid residues 225-240 (YDMVGI QGSDSVFSGF) of SEQ ID NO: 41 (SEQ ID NO:48); (c) amino acid residues 225-232 of SEQ ID NO: 41 (SEQ ID NO:49) or amino acid residues of a ClqC corresponding to amino acid residues 225-232 (YDMVG
• Suitable inhibitors include an antibody that binds complement Cls protein (i.e., an anti-complement Cls antibody, also referred to herein as an anti-Cls antibody and a Cls antibody) and a nucleic acid molecule that encodes such an antibody.
• complement Cls i.e., an anti-complement Cls antibody, also referred to herein as an anti-Cls antibody and a Cls antibody
• nucleic acid molecule that encodes such an antibody.
• Complement Cls is an attractive target as it is upstream in the complement cascade and has a narrow range of substrate specificity.
• antibodies for example, but not limited to, monoclonal antibodies
• the antibody may be a murine, humanized, or chimeric antibody.
• the light chain variable domain comprises HVR-L1, HVR-L2, and HVR-L3
• the heavy chain comprises HVR-Hl, HVR-H2, and HVR-H3 of a murine anti-human Cls monoclonal antibody 5A1 produced by a hybridoma cell line deposited with ATCC on 5/15/2013 or progeny thereof (ATCC Accession No. PTA-120351).
• the light chain variable domain comprises the HVR-Ll, HVR-L2, and HVR-L3 and the heavy chain variable domain comprises the HVR-Hl, HVR-H2, and HVR-H3 of a murine anti-human Cls monoclonal antibody 5C12 produced by a hybridoma cell line deposited with ATCC on 5/15/2013, or progeny thereof (ATCC Accession No. PTA-120352).
• antibodies specifically bind to and inhibit a biological activity of C 1 s or the C 1 s proenzyme, such as C 1 s binding to C 1 q, C 1 s binding to C 1 r, or C 1 s binding to C2 or C4.
• the biological activity may be a proteolytic enzyme activity of Cls, the conversion of the Cls proenzyme to an active protease, or proteolytic cleavage of C2 or C4.
• the biological activity is activation of the classical complement activation pathway, activation of antibody and complement dependent cytotoxicity, or C1F hemolysis.
• the method comprises administering a humanized monoclonal antibody that binds complement component Cls in a CI complex with high avidity.
• an anti-Cls antibody with one or more of the complementarity determining regions (CDRs) of an antibody light chain variable region comprising amino acid sequence SEQ ID NO:57 and/or one or more of the CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO:58.
• the anti-Cls antibody may bind a human or rat complement Cls protein.
• an anti-Cls antibody inhibits cleavage of at least one substrate cleaved by complement Cls protein.
• the antibody comprises: a) a complementarity determining region (CDR) having an amino acid sequence selected from SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, and SEQ ID NO:56; and/ or b) a CDR having an amino acid sequence selected from SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO:53, SEQ ID NO:64, SEQ ID NO:65: and SEQ ID NO:66.
• CDR complementarity determining region
• the antibody may comprise a CDR-L1 having amino acid sequence SEQ ID NO:51, a CDR-L2 having amino acid sequence SEQ ID NO: 52, a CDR-L3 having amino acid sequence SEQ ID NO:53, a CDR-H1 having amino acid sequence SEQ ID NO:54, a CDR- H2 having amino acid sequence SEQ ID NO:55, and a CDR-H3 having amino acid sequence SEQ ID NO:56.
• the antibody may comprise light chain CDRs of a variable region with an amino acid sequence of SEQ ID NO:67, and/or heavy chain CDRs of a variable region with an amino acid sequence of SEQ ID NO: 68.
• the antibody can be a humanized antibody that specifically binds complement component Cls, wherein the antibody competes for binding the epitope with an antibody that comprises one or more of the CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO: 57 or SEQ ID NO: 67, and/or one or more of the CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO:58 or SEQ ID NO:68.
• the antibody can be a humanized antibody that specifically binds complement Cls, wherein the antibody is selected from: a) a humanized antibody that specifically binds an epitope within the complement Cls protein, wherein the antibody competes for binding the epitope with an antibody that comprises a CDR having an amino acid sequence selected from SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, and SEQ ID NO:56; and b) a humanized antibody that specifically binds an epitope within the complement Cls protein, wherein the antibody competes for binding the epitope with an antibody that comprises a CDR having an amino acid sequence selected from SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:53, SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66.
• the antibody competes for binding the epitope with an antibody that comprises heavy and light chain CDRs comprising: a) SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:69, SEQ ID NO:55, and SEQ ID NO:56; or b) SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:53, SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66.
• the antibody may comprise a light chain region and a heavy chain region that are present in separate polypeptides.
• the antibody may comprise an Fc region.
• an anti-Cls antibody comprising a light chain variable region of an amino acid sequence that is 90% identical to amino acid sequence SEQ ID NO:57, and a heavy chain variable region comprising an amino acid sequence that is 90% identical to amino acid sequence SEQ ID NO: 58.
• the anti-Cls antibody may be selected from an antigen binding fragment, Ig monomer, a Fab fragment, a F(ab') 2 fragment, a Fd fragment, a scFv, a scAb, a dAb, a Fv, a single domain heavy chain antibody, a single domain light chain antibody, a mono-specific antibody, a bi-specific antibody, or a multi-specific antibody.
• an antibody that competes for binding the epitope bound by antibody IPN003 (also referred to herein as "IPN-M34" or "M34" or "TNT003”), e.g., an antibody comprising a variable domain of antibody IPN003, such as antibody IPN003.
• the method comprises administering an antibody that specifically binds an epitope within a complement Cls protein.
• the isolated anti-Cls antibody binds an activated Cls protein.
• the isolated anti-Cls antibody binds an inactive form of Cls. In other instances, the isolated anti-Cls antibody binds both an activated Cls protein and an inactive form of Cls.
• the method comprises administering a monoclonal antibody that inhibits cleavage of C4, where the isolated monoclonal antibody does not inhibit cleavage of C2. In some embodiments, the method comprises administering a monoclonal antibody that inhibits cleavage of C2, where the isolated monoclonal antibody does not inhibit cleavage of C4. In some cases, the isolated monoclonal antibody is humanized. In some cases, the antibody inhibits a component of the classical complement pathway. In some cases, the component of the classical complement pathway that is inhibited by the antibody is Cls.
• the present disclosure also provides methods of treating a complement-mediated disease or disorder, by administering to an individual in need thereof an isolated monoclonal antibody that inhibits cleavage of C4, or a pharmaceutical composition comprising the isolated monoclonal antibody, where the isolated monoclonal antibody does not inhibit cleavage of C2.
• the method comprises administering a monoclonal antibody that inhibits cleavage of C2 or C4 by Cls, i.e., inhibits Cls-mediated proteolytic cleavage of C2 or C4.
• the monoclonal antibody is humanized.
• the antibody inhibits cleavage of C2 or C4 by Cls by inhibiting binding of C2 or C4 to Cls; for example, in some cases, the antibody inhibits Cls-mediated cleavage of C2 or C4 by inhibiting binding of C2 or C4 to a C2 or C4 binding site of Cls.
• the antibody functions as a competitive inhibitor.
• the present disclosure also provides methods of treating frontotemporal dementia, by administering to an individual in need thereof an isolated monoclonal antibody that inhibits cleavage of C2 or C4 by Cls, i.e., inhibits Cls-mediated proteolytic cleavage of C2 or C4.
• the method comprises administering a monoclonal antibody that inhibits cleavage of C4 by Cls, where the antibody does not inhibit cleavage of complement component C2 by Cls; i.e., the antibody inhibits Cls-mediated cleavage of C4, but does not inhibit Cls-mediated cleavage of C2.
• the monoclonal antibody is humanized. In some cases, the monoclonal antibody inhibits binding of C4 to Cls, but does not inhibit binding of C2 to Cls.
• the method comprises treating a complement-mediated disease or disorder, by administering to an individual in need thereof an isolated monoclonal antibody that inhibits cleavage of C4 by Cl s, where the antibody does not inhibit cleavage of complement component C2 by Cls; i.e., the antibody inhibits Cls-mediated cleavage of C4, but does not inhibit Cls-mediated cleavage of C2.
• the antibody is humanized.
• the method comprises administering a humanized monoclonal antibody that specifically binds an epitope within a region encompassing domains IV and V of Cls.
• the humanized monoclonal antibody specifically binds an epitope within amino acids 272-422 of the amino acid sequence depicted in FIG. 1 and set forth in SEQ ID NO:70.
• the humanized monoclonal antibody specifically binds an epitope within amino acids 272-422 of the amino acid sequence depicted in FIG. 1 and set forth in SEQ ID NO:70, and inhibits binding of C4 to Cls.
• the method comprises treating a complement-mediated disease or disorder, by administering to an individual in need thereof a humanized monoclonal antibody that specifically binds an epitope within amino acids 272-422 of the amino acid sequence depicted in FIG. 1 and set forth in SEQ ID NO: 70, and inhibits binding of C4 to Cls.
• the method comprises administering a humanized monoclonal antibody that specifically binds a conformational epitope within a region encompassing domains IV and V of Cls.
• a humanized monoclonal antibody that specifically binds a conformational epitope within amino acids 272-422 of the amino acid sequence depicted in FIG. 1 and set forth in SEQ ID NO:70.
• the humanized monoclonal antibody specifically binds a conformational epitope within amino acids 272-422 of the amino acid sequence depicted in FIG. 1 and set forth in SEQ ID NO: 70, and inhibits binding of C4 to Cls.
• the method comprises frontotemporal dementia, the method comprising administering to an individual in need thereof a humanized monoclonal antibody that specifically binds a conformational epitope within amino acids 272-422 of the amino acid sequence depicted in FIG. 1 and set forth in SEQ ID NO: 70, and inhibits binding of C4 to Cls.
• the method comprises administering a monoclonal antibody that binds complement component Cl s in a C I complex.
• the C I complex is composed of 6 molecules of Clq, 2 molecules of Clr, and 2 molecules of Cl s.
• the monoclonal antibody is humanized.
• the antibody binds Cl s present in a C I complex with high avidity.
• the anti-Cl s antibody (e.g., a subject antibody that specifically binds an epitope in a complement C l s protein) comprises: a) a light chain region comprising one, two, or three VL CDRs of an IPN003 antibody; and b) a heavy chain region comprising one, two, or three VH CDRs of an IPN003 antibody; where the VH and VL CDRs are as defined by Kabat (see, e.g., Table 1 ; and Kabat 1991).
• the anti-C l s antibody (e.g., a subject antibody that specifically binds an epitope in a complement C l s protein) comprises: a) a light chain region comprising one, two, or three VL CDRs of an IPN003 antibody; and b) a heavy chain region comprising one, two, or three VH CDRs of an IPN003 antibody; where the VH and VL CDRs are as defined by Chothia (see, e.g., Table 1, and Chothia 1987).
• CDR amino acid sequences, and VL and VH amino acid sequences, of IPN003 antibody are provided in Table 2.
• Table 2 also provides the SEQ ID NOs assigned to each of the amino acid sequences.
• the anti-Cl s antibody (e.g., a subject antibody that specifically binds an epitope in a complement C l s protein) comprises: a) a light chain region comprising one, two, or three CDRs selected from SEQ ID NO:51, SEQ ID NO:52, and SEQ ID NO:53; and b) a heavy chain region comprising one, two, or three CDRs selected from SEQ ID NO:54, SEQ ID NO:55, and SEQ ID NO:56.
• the anti-Cl s antibody includes a humanized VH and/or VL framework region.
• SEQ ID NO. 51 SSVSSSYLHWYQ;
• SEQ ID NO. 52 STSNLASGVP
• SEQ ID NO. 53 HQYYRLPPIT
• SEQ ID NO. 54 GFTF SNYAMSWV;
• SEQ ID NO. 55 ISSGGSHTYY
• SEQ ID NO. 56 ARLFTGYAMDY.
• the anti-Cls antibody comprises a CDR having an amino acid sequence selected from SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, and SEQ ID NO:56.
• the anti-Cls antibody comprises a light chain variable region comprising amino acid sequences SEQ ID NO:51, SEQ ID NO:52, and SEQ ID NO:53.
• the anti-Cls antibody comprises a heavy chain variable region comprising amino acid sequences SEQ ID NO:54, SEQ ID NO:55, and SEQ ID NO:56.
• the anti-Cls antibody comprises a CDR-L1 having amino acid sequence SEQ ID NO: 51, a CDR-L2 having amino acid sequence SEQ ID NO: 52, a CDR-L3 having amino acid sequence SEQ ID NO:53, a CDR-H1 having amino acid sequence SEQ ID NO:54, a CDR-H2 having amino acid sequence SEQ ID NO:55, and a CDR-H3 having amino acid sequence SEQ ID NO: 56.
• the anti-Cls antibody comprises a light chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:57.
• the anti-Cls antibody comprises a heavy chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO. 58.
• the anti-Cls antibody comprises a light chain variable region comprising an amino acid sequence that is 90% identical to amino acid sequence SEQ ID NO:57. In some embodiments, the anti-Cl s antibody comprises a heavy chain variable region comprising an amino acid sequence that is 90% identical to amino acid sequence SEQ ID NO:58.
• the anti-Cl s antibody comprises a light chain variable region comprising amino acid sequence SEQ ID NO:57.
• the anti-Cl s antibody comprises a heavy chain variable region comprising amino acid sequence SEQ ID NO:58.
• the anti-Cl s antibody comprises a light chain variable region comprising an amino acid sequence that is 90% identical to amino acid sequence SEQ ID NO:57 and a heavy chain variable region comprising an amino acid sequence that is 90% identical to amino acid sequence SEQ ID NO: 58.
• the anti-Cl s antibody comprises a light chain variable region comprising amino acid sequence SEQ ID NO:57 and a heavy chain variable region comprising amino acid sequence SEQ ID NO:58.
• the anti-Cl s antibody specifically binds an epitope within the complement C l s protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO:57 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO: 58.
• the anti-Cl s antibody comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO:57 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO: 58.
• the anti-Cl s antibody (e.g., a subject antibody that specifically binds an epitope in a complement C l s protein) comprises: a) a light chain region comprising one, two, or three CDRs selected from SEQ ID NO:62, SEQ ID NO:63, and SEQ ID NO:53; and b) a heavy chain region comprising one, two, or three CDRs selected from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66.
• SEQ ID N0.62 TASSSVSSSYLH
• SEQ ID NO. 63 STSNLAS
• SEQ ID N0.65 TISSGGSHTYYLDSVKG
• the anti-Cls antibody comprises a CDR having an amino acid sequence selected from SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:53, SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66.
• the anti-Cls antibody comprises a light chain variable region comprising amino acid sequences SEQ ID NO:62, SEQ ID NO:63, and SEQ ID NO:53.
• the anti-Cls antibody comprises a heavy chain variable region comprising amino acid sequences SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66.
• the anti-Cls antibody comprises a CDR-L1 having amino acid sequence SEQ ID NO: 62, a CDR-L2 having amino acid sequence SEQ ID NO: 63, a CDR-L3 having amino acid sequence SEQ ID NO:53, a CDR-H1 having amino acid sequence SEQ ID NO:64, a CDR-H2 having amino acid sequence SEQ ID NO:65, and a CDR-H3 having amino acid sequence SEQ ID NO: 66.
• the anti-Cls antibody comprises a light chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:67.
• the anti-Cls antibody comprises a heavy chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:68.
• the anti-Cls antibody comprises a light chain variable region comprising an amino acid sequence that is 90% identical to amino acid sequence SEQ ID NO:67.
• the anti-Cls antibody comprises a heavy chain variable region comprising an amino acid sequence that is 90% identical to amino acid sequence SEQ ID NO:68.
• the anti-Cls antibody comprises a light chain variable region comprising amino acid sequence SEQ ID NO:67.
• the anti-Cls antibody comprises a heavy chain variable region comprising amino acid sequence SEQ ID NO:68.
• the anti-Cls antibody comprises a light chain variable region comprising an amino acid sequence that is 90% identical to amino acid sequence SEQ ID NO:67 and a heavy chain variable region comprising an amino acid sequence that is 90% identical to amino acid sequence SEQ ID NO: 68.
• the anti-Cls antibody comprises a light chain variable region comprising an amino acid sequence that is 95% identical to amino acid sequence SEQ ID NO:67 and a heavy chain variable region comprising an amino acid sequence that is 95% identical to amino acid sequence SEQ ID NO: 68.
• the anti-Cls antibody comprises a light chain variable region comprising amino acid sequence SEQ ID NO:67 and a heavy chain variable region comprising amino acid sequence SEQ ID NO:68.
• the anti-Cls antibody specifically binds an epitope within the complement Cls protein, wherein the antibody competes for binding the epitope with an antibody that comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO:67 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO: 68.
• the anti-Cls antibody comprises light chain CDRs of an antibody light chain variable region comprising amino acid sequence SEQ ID NO:67 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO: 68.
• the anti-Cls antibody comprises a light chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:67.
• the anti-Cls antibody comprises a heavy chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO:68.
• An anti-Cls antibody can comprise a heavy chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:79 and depicted in FIG. 2 (VH variant 1).
• An anti-Cls antibody can comprise a heavy chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:80 and depicted in FIG. 3 (VH variant 2).
• An anti-Cls antibody can comprise a heavy chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:81 and depicted in FIG. 4 (VH variant 3).
• An anti-Cls antibody can comprise a heavy chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:82 and depicted in FIG. 5 (VH variant 4).
• An anti-Cls antibody can comprise a light chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 83 and depicted in FIG. 6 (VK variant 1).
• An anti-Cls antibody can comprise a light chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 84 and depicted in FIG. 7 (VK variant 2).
• An anti-Cls antibody can comprise a light chain variable region comprising an amino acid sequence that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence set forth in SEQ ID NO:85 and depicted in FIG. 8 (VK variant 3).
• An anti-Cls antibody can comprise a heavy chain variable region comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 of the framework (FR) amino acid substitutions, relative to the IPN003 parental antibody FR amino acid sequences, depicted in Table 3 (FIG. 9).
• a or “an” may mean one or more.
• the words “a” or “an” when used in conjunction with the word “comprising”, the words “a” or “an” may mean one or more than one.
• reference to an "antibody” is a reference from one to many antibodies.
• another may mean at least a second or more.
• administration in conjunction with another compound or composition includes simultaneous administration and/or administration at different times.
• Administration in conjunction also encompasses administration as a co-formulation or administration as separate compositions, including at different dosing frequencies or intervals, and using the same route of administration or different routes of administration.
• immunoglobulin (Ig) is used interchangeably with “antibody” herein.
• antibody herein is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, multispecific antibodies ⁇ e.g., bispecific antibodies) formed from at least two intact antibodies, and antibody fragments so long as they exhibit the desired biological activity.
• the basic 4-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains.
• L light
• H heavy
• the pairing of a VH and VL together forms a single antigen-binding site.
• L light
• H heavy
• immunoglobulins can be assigned to different classes or isotypes. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, having heavy chains designated alpha ("a"), delta (" ⁇ "), epsilon (“ ⁇ ”), gamma (“ ⁇ ”) and mu (“ ⁇ ”), respectively.
• the ⁇ and a classes are further divided into subclasses (isotypes) on the basis of relatively minor differences in the CH sequence and function, e.g., humans express the following subclasses: IgGl, IgG2, IgG3, IgG4, IgAl, and IgA2.
• subclasses immunoglobulins
• the subunit structures and three dimensional configurations of different classes of immunoglobulins are well known and described generally in, for example, Abbas et al, Cellular and Molecular Immunology, 4 th ed. (W.B. Saunders Co., 2000).
• “Native antibodies” are usually heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (VH) followed by a number of constant domains.
• VH variable domain
• Each light chain has a variable domain at one end (VL) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are believed to form an interface between the light chain and heavy chain variable domains.
• an "isolated' molecule or cell is a molecule or a cell that is identified and separated from at least one contaminant molecule or cell with which it is ordinarily associated in the environment in which it was produced.
• the isolated molecule or cell is free of association with all components associated with the production environment.
• the isolated molecule or cell is in a form other than in the form or setting in which it is found in nature. Isolated molecules therefore are distinguished from molecules existing naturally in cells; isolated cells are distinguished from cells existing naturally in tissues, organs, or individuals.
• the isolated molecule is an anti-Cls, anti-Clq, or anti-Clr antibody of the present disclosure.
• the isolated cell is a host cell or hybridoma cell producing an anti-Cls, anti-Clq, or anti-Clr antibody of the present disclosure.
• an "isolated' antibody is one that has been identified, separated and/or recovered from a component of its production environment ⁇ e.g., naturally or recombinantly).
• the isolated polypeptide is free of association with all other contaminant components from its production environment.
• Contaminant components from its production environment such as those resulting from recombinant transfected cells, are materials that would typically interfere with research, diagnostic or therapeutic uses for the antibody, and may include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes.
• the polypeptide will be purified: (1) to greater than 95% by weight of antibody as determined by, for example, the Lowry method, and in some embodiments, to greater than 99% by weight; (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver stain.
• An isolated antibody includes the antibody in situ within recombinant T-cells since at least one component of the antibody's natural environment will not be present. Ordinarily, however, an isolated polypeptide or antibody will be prepared by a process including at least one purification step.
• variable region refers to the amino- terminal domains of the heavy or light chain of the antibody.
• variable domains of the heavy chain and light chain may be referred to as "VH” and “VL”, respectively. These domains are generally the most variable parts of the antibody (relative to other antibodies of the same class) and contain the antigen binding sites.
• variable refers to the fact that certain segments of the variable domains differ extensively in sequence among antibodies.
• the V domain mediates antigen binding and defines the specificity of a particular antibody for its particular antigen.
• variability is not evenly distributed across the entire span of the variable domains. Instead, it is concentrated in three segments called hypervariable regions (HVRs) both in the light-chain and the heavy chain variable domains.
• HVRs hypervariable regions
• the more highly conserved portions of variable domains are called the framework regions (FR).
• the variable domains of native heavy and light chains each comprise four FR regions, largely adopting a beta-sheet configuration, connected by three HVRs, which form loops connecting, and in some cases forming part of, the beta-sheet structure.
• the HVRs in each chain are held together in close proximity by the FR regions and, with the HVRs from the other chain, contribute to the formation of the antigen binding site of antibodies ⁇ see Kabat et al., Sequences of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, MD (1991)).
• the constant domains are not involved directly in the binding of antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent-cellular toxicity.
• CDR complementarity determining region
• CDRs have been described by Kabat et al., J. Biol. Chem. 252:6609-6616 (1977); Kabat et al., U.S. Dept. of Health and Human Services, "Sequences of proteins of immunological interest” (1991) (also referred to herein as Kabat 1991); by Chothia et al., J. Mol. Biol. 196:901-917 (1987) (also referred to herein as Chothia 1987); and MacCallum et al., J. Mol. Biol.
• Residue numbering follows the nomenclature of Kabat et al., supra
• CDR-L1 refers, respectively, to the first, second, and third CDRs in a light chain variable region.
• CDR-H1 refers, respectively, to the first, second, and third CDRs in a heavy chain variable region.
• CDR-1 refers, respectively, to the first, second and third CDRs of either chain's variable region.
• monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies of the population are identical except for possible naturally occurring mutations and/or post- translation modifications (e.g., isomerizations, amidations) that may be present in minor amounts.
• Monoclonal antibodies are highly specific, being directed against a single antigenic site.
• polyclonal antibody preparations which typically include different antibodies directed against different determinants (epitopes)
• each monoclonal antibody is directed against a single determinant on the antigen.
• monoclonal antibodies are advantageous since they are typically synthesized by hybridoma culture, uncontaminated by other immunoglobulins.
• the modifier "monoclonal” indicates the character of the antibody as being obtained as a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
• the monoclonal antibodies to be used in accordance with the present disclosure may be made by a variety of techniques, including, for example, the hybridoma method (e.g., Kohler and Milstein., Nature, 256:495-97 (1975); Hongo et al., Hybridoma, 14 (3):253-260 (1995), Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2d ed.
• the terms ''fall-length antibody,” “intact antibody” and “whole antibody” are used interchangeably to refer to an antibody in its substantially intact form, as opposed to an antibody fragment. Specifically, whole antibodies include those with heavy and light chains including an Fc region.
• the constant domains may be native sequence constant domains ⁇ e.g., human native sequence constant domains) or amino acid sequence variants thereof. In some cases, the intact antibody may have one or more effector functions.
• antibody fragment comprises a portion of an intact antibody, preferably the antigen binding and/or the variable region of the intact antibody.
• antibody fragments include Fab, Fab', F(ab') 2 and Fv fragments; diabodies; linear antibodies ⁇ see U.S. Patent 5,641,870, Example 2; Zapata et al., Protein Eng. 8(10): 1057-1062 (1995)); single- chain antibody molecules and multispecific antibodies formed from antibody fragments.
• Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, and a residual "Fc” fragment, a designation reflecting the ability to crystallize readily.
• the Fab fragment consists of an entire L chain along with the variable region domain of the H chain (VH), and the first constant domain of one heavy chain (CHI).
• VH variable region domain of the H chain
• CHI first constant domain of one heavy chain
• Each Fab fragment is monovalent with respect to antigen binding, i.e., it has a single antigen- binding site.
• Pepsin treatment of an antibody yields a single large F(ab') 2 fragment which roughly corresponds to two disulfide linked Fab fragments having different antigen-binding activity and is still capable of cross-linking antigen.
• Fab' fragments differ from Fab fragments by having a few additional residues at the carboxy terminus of the CHI domain including one or more cysteines from the antibody hinge region.
• Fab'-SH is the designation herein for Fab' in which the cysteine residue(s) of the constant domains bear a free thiol group.
• F(ab') 2 antibody fragments originally were produced as pairs of Fab' fragments with hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
• the Fc fragment comprises the carboxy-terminal portions of both H chains held together by disulfides.
• the effector functions of antibodies are determined by sequences in the Fc region, the region which is also recognized by Fc receptors (FcR) found on certain types of cells.
• Fc region herein is used to define a C-terminal region of an immunoglobulin heavy chain, including native-sequence Fc regions and variant Fc regions.
• the human IgG heavy-chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof.
• the C-terminal lysine (residue 447 according to the EU numbering system) of the Fc region may be removed, for example, during production or purification of the antibody, or by recombinantly engineering the nucleic acid encoding a heavy chain of the antibody.
• composition of intact antibodies may comprise antibody populations with all K447 residues removed, antibody populations with no K447 residues removed, and antibody populations having a mixture of antibodies with and without the K447 residue.
• Suitable native-sequence Fc regions for use in the antibodies of the disclosure include human IgGl, IgG2, IgG3 and IgG4.
• a “native sequence Fc region” comprises an amino acid sequence identical to the amino acid sequence of an Fc region found in nature.
• Native sequence human Fc regions include a native sequence human IgGl Fc region (non-A and A allotypes); native sequence human IgG2 Fc region; native sequence human IgG3 Fc region; and native sequence human IgG4 Fc region as well as naturally occurring variants thereof.
• a “variant Fc region” comprises an amino acid sequence which differs from that of a native sequence Fc region by virtue of at least one amino acid modification, preferably one or more amino acid substitution(s).
• the variant Fc region has at least one amino acid substitution compared to a native sequence Fc region or to the Fc region of a parent polypeptide, e.g., from about one to about ten amino acid substitutions, and preferably from about one to about five amino acid substitutions in a native sequence Fc region or in the Fc region of the parent polypeptide.
• the variant Fc region herein will preferably possess at least about 80% homology with a native sequence Fc region and/or with an Fc region of a parent polypeptide, and most preferably at least about 90% homology therewith, more preferably at least about 95% homology therewith.
• Fc receptor or “FcR' describes a receptor that binds to the Fc region of an antibody.
• the preferred FcR is a native sequence human FcR.
• a preferred FcR is one which binds an IgG antibody (a gamma receptor) and includes receptors of the FcyRI, FcyRII, and FcyRIII subclasses, including allelic variants and alternatively spliced forms of these receptors, FcyRII receptors include FcyRIIA (an “activating receptor”) and FcyRIIB (an “inhibiting receptor”), which have similar amino acid sequences that differ primarily in the cytoplasmic domains thereof.
• Activating receptor FcyRIIA contains an immunoreceptor tyrosine-based activation motif ("ITAM”) in its cytoplasmic domain.
• Inhibiting receptor FcyRIIB contains an immunoreceptor tyrosine-based inhibition motif ("ITIM") in its cytoplasmic domain.
• ITAM immunoreceptor tyrosine-based activation motif
• ITIM immunoreceptor tyrosine-based inhibition motif
• Binding to FcRn in vivo and serum half-life of human FcRn high-affinity binding polypeptides can be assayed, e.g., in transgenic mice or transfected human cell lines expressing human FcRn, or in primates to which the polypeptides having a variant Fc region are administered.
• WO 2004/42072 (Presta) describes antibody variants with improved or diminished binding to FcRs. See also, e.g., Shields et al., J. Biol. Chem. 9(2):6591-6604 (2001).
• v is the minimum antibody fragment, which contains a complete antigen- recognition and -binding site. This fragment consists of a dimer of one heavy- and one light- chain variable region domain in tight, non-covalent association. From the folding of these two domains emanate six hypervariable loops (3 loops each from the H and L chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three HVRs specific for an antigen) has the ability to recognize and bind antigen, although at a lower affinity than the entire binding site.
• Single-chain Fv also abbreviated as “sFv” or “scFv” are antibody fragments that comprise the VH and VL antibody domains connected into a single polypeptide chain.
• the sFv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the sFv to form the desired structure for antigen binding.
• Pliickthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer- Verlag, New York, pp. 269-315 (1994).
• Fully fragments ' " of antibodies comprise a portion of an intact antibody, generally including the antigen binding or variable region of the intact antibody or the F region of an antibody which retains or has modified FcR binding capability.
• antibody fragments include linear antibody, single-chain antibody molecules and multispecific antibodies formed from antibody fragments.
• diabodies refers to small antibody fragments prepared by constructing sFv fragments (see preceding paragraph) with short linkers (about 5-10) residues) between the VH and VL domains such that inter-chain but not intra-chain pairing of the V domains is achieved, thereby resulting in a bivalent fragment, i.e., a fragment having two antigen- binding sites.
• Bispecific diabodies are heterodimers of two "crossover" sFv fragments in which the VH and VL domains of the two antibodies are present on different polypeptide chains.
• Diabodies are described in greater detail in, for example, EP 404,097; WO 1993/011161; WO/2009/121948; WO/2014/191493; Hollinger et al., Proc. Nat ⁇ Acad. Sci. USA 90:6444-48 (1993).
• a "chimeric antibody” refers to an antibody (immunoglobulin) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is(are) identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U.S. Patent No. 4,816,567; Morrison et al., Proc. Nat l Acad. Sci. USA, 81 :6851-55 (1984)).
• Chimeric antibodies of interest herein include PRIMATIZED ® antibodies wherein the antigen-binding region of the antibody is derived from an antibody produced by, e.g., immunizing macaque monkeys with an antigen of interest.
• "humanized antibody” is a subset of “chimeric antibodies.”
• Humanized' forms of non-human ⁇ e.g., murine antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin.
• a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from an HVR of the recipient are replaced by residues from an HVR of a non- human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired specificity, affinity, and/or capacity.
• donor antibody such as mouse, rat, rabbit or non-human primate having the desired specificity, affinity, and/or capacity.
• FR residues of the human immunoglobulin are replaced by corresponding non-human residues.
• humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications may be made to further refine antibody performance, such as binding affinity.
• a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin sequence, and all or substantially all of the FR regions are those of a human immunoglobulin sequence, although the FR regions may include one or more individual FR residue substitutions that improve antibody performance, such as binding affinity, isomerization, immunogenicity, and the like.
• the number of these amino acid substitutions in the FR is typically no more than 6 in the H chain, and in the L chain, no more than 3.
• the humanized antibody optionally will also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
• Fc immunoglobulin constant region
• a "human antibody” is one that possesses an amino-acid sequence corresponding to that of an antibody produced by a human and/or has been made using any of the techniques for making human antibodies as disclosed herein. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
• Human antibodies can be produced using various techniques known in the art, including phage-display libraries. Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991). Also available for the preparation of human monoclonal antibodies are methods described in Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p.
• Human antibodies can be prepared by administering the antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled, e.g., immunized xenomice (see, e.g., U.S. Patent Nos. 6,075,181 and 6,150,584 regarding XENOMOUSETM technology). See also, for example, Li et al., Proc. Nat 'l Acad. Sci. USA, 103 :3557-3562 (2006) regarding human antibodies generated via a human B-cell hybridoma technology.
• hypervariable region when used herein refers to the regions of an antibody-variable domain that are hypervariable in sequence and/or form structurally defined loops.
• antibodies comprise six HVRs; three in the VH (HI, H2, H3), and three in the VL (LI, L2, L3).
• H3 and L3 display the most diversity of the six HVRs, and H3 in particular is believed to play a unique role in conferring fine specificity to antibodies.
• HVR delineations are in use and are encompassed herein.
• the HVRs that are Kabat complementarity-determining regions (CDRs) are based on sequence variability and are the most commonly used (Kabat et al., supra). Chothia refers instead to the location of the structural loops (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).
• the AbM HVRs represent a compromise between the Kabat CDRs and Chothia structural loops, and are used by Oxford Molecular's AbM antibody-modeling software.
• the "contact" HVRs are based on an analysis of the available complex crystal structures. The residues from each of these HVRs are noted below.
• H3 H95-H102 H95-H102 H96-H101 H93-H101 HVRs may comprise "extended HVRs" as follows: 24-36 or 24-34 (LI), 46-56 or 50- 56 (L2), and 89-97 or 89-96 (L3) in the VL, and 26-35 (HI), 50-65 or 49-65 (a preferred embodiment) (H2), and 93-102, 94-102, or 95-102 (H3) in the VH.
• the variable-domain residues are numbered according to Kabat et al., supra, for each of these extended-HVR definitions.
• Framework or "FR” residues are those variable-domain residues other than the HVR residues as herein defined.
• variable-domain residue-numbering as in Kabat or “amino-acid- position numbering as in Kabat” and variations thereof, refers to the numbering system used for heavy-chain variable domains or light-chain variable domains of the compilation of antibodies in Kabat et al., supra. Using this numbering system, the actual linear amino acid sequence may contain fewer or additional amino acids corresponding to a shortening of, or insertion into, a FR or HVR of the variable domain.
• a heavy-chain variable domain may include a single amino acid insert (residue 52a according to Kabat) after residue 52 of H2 and inserted residues ⁇ e.g., residues 82a, 82b, and 82c, etc. according to Kabat) after heavy-chain FR residue 82.
• the Kabat numbering of residues may be determined for a given antibody by alignment at regions of homology of the sequence of the antibody with a "standard" Kabat numbered sequence.
• the Kabat numbering system is generally used when referring to a residue in the variable domain (approximately residues 1-107 of the light chain and residues 1-113 of the heavy chain) ⁇ e.g., Kabat et al., Sequences of Immunological Interest. 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)).
• the "EU numbering system” or "EU index” is generally used when referring to a residue in an immunoglobulin heavy chain constant region ⁇ e.g., the EU index reported in Kabat et al, supra).
• the "EU index as in Kabat” refers to the residue numbering of the human IgGl EU antibody.
• references to residue numbers in the variable domain of antibodies means residue numbering by the Kabat numbering system. Unless stated otherwise herein, references to residue numbers in the constant domain of antibodies means residue numbering by the EU numbering system ⁇ e.g., see United States Patent Publication No. 2010-280227).
• acceptor human framework is a framework comprising the amino acid sequence of a VL or VH framework derived from a human immunoglobulin framework or a human consensus framework.
• An acceptor human framework "derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain pre-existing amino acid sequence changes. In some embodiments, the number of pre-existing amino acid changes are 10 or fewer, 9 or fewer, 8 or fewer, 7 or fewer, 6 or fewer, 5 or fewer, 4 or fewer, 3 or fewer, or 2 or fewer.
• VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence.
• a "human consensus framework” is a framework that represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences.
• the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences.
• the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991). Examples include for the VL, the subgroup may be subgroup kappa I, kappa II, kappa III or kappa IV as in Kabat et al, supra. Additionally, for the VH, the subgroup may be subgroup I, subgroup II, or subgroup III as in Kabat et al., supra.
• amino-acid modification at a specified position refers to the substitution or deletion of the specified residue, or the insertion of at least one amino acid residue adjacent the specified residue. Insertion "adjacent" to a specified residue means insertion within one to two residues thereof. The insertion may be N-terminal or C-terminal to the specified residue.
• the preferred amino acid modification herein is a substitution.
• an "affinity-matured' antibody is one with one or more alterations in one or more HVRs thereof that result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody that does not possess those alteration(s).
• an affinity-matured antibody has nanomolar or even picomolar affinities for the target antigen.
• Affinity-matured antibodies are produced by procedures known in the art. For example, Marks et al., Bio/Technology 10:779-783 (1992) describes affinity maturation by VH- and VL-domain shuffling. Random mutagenesis of HVR and/or framework residues is described by, for example: Barbas et al. Proc Nat. Acad. Sci.
• an antibody that specifically or preferentially binds to a target or an epitope is an antibody that binds this target or epitope with greater affinity, avidity, more readily, and/or with greater duration than it binds to other targets or other epitopes of the target. It is also understood that, for example, an antibody (or a moiety) that specifically or preferentially binds to a first target may or may not specifically or preferentially bind to a second target. As such, “specific binding” or “preferential binding” does not necessarily require (although it can include) exclusive binding.
• An antibody that specifically binds to a target may have an association constant of at least about 10 3 M “1 or 10 4 M “1 , sometimes about 10 5 M “1 or 10 6 M “1 , in other instances about 10 6 M _1 or 10 7 M _1 , about 10 8 M _1 to 10 9 M _1 , or about lO ⁇ M ⁇ to 10 11 M “1 or higher.
• a variety of immunoassay formats can be used to select antibodies specifically immunoreactive with a particular protein.
• solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See, e.g., Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity.
• an “interaction" between a complement protein and a second protein encompasses, without limitation, protein-protein interaction, a physical interaction, a chemical interaction, binding, covalent binding, and ionic binding.
• an antibody “inhibits interaction” between two proteins when the antibody disrupts, reduces, or completely eliminates an interaction between the two proteins.
• An antibody of the present disclosure, or fragment thereof "inhibits interaction” between two proteins when the antibody or fragment thereof binds to one of the two proteins.
• neutralizing antibody is an antibody that inhibits or reduces one or more biological activities of the antigen it binds, such as interactions with one or more proteins.
• blocking antibodies, antagonist antibodies, inhibitory antibodies, or “neutralizing” antibodies substantially or completely inhibit one or more biological activities or interactions of the antigen.
• Antibody effector functions refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody, and vary with the antibody isotype.
• affinity refers to the equilibrium constant for the reversible binding of two agents ⁇ e.g., an antibody and an antigen) and is expressed as a dissociation constant (KD).
• KD dissociation constant
• Affinity can be at least 1-fold greater, at least 2-fold greater, at least 3 -fold greater, at least 4-fold greater, at least 5-fold greater, at least 6-fold greater, at least 7-fold greater, at least 8-fold greater, at least 9-fold greater, at least 10-fold greater, at least 20-fold greater, at least 30-fold greater, at least 40-fold greater, at least 50-fold greater, at least 60- fold greater, at least 70-fold greater, at least 80-fold greater, at least 90-fold greater, at least 100-fold greater, or at least 1,000-fold greater, or more, than the affinity of an antibody for unrelated amino acid sequences.
• Affinity of an antibody to a target protein can be, for example, from about 100 nanomolar (nM) to about 0.1 nM, from about 100 nM to about 1 picomolar (pM), or from about 100 nM to about 1 femtomolar (fJVI) or more.
• nM nanomolar
• pM picomolar
• fJVI femtomolar
• the term “avidity” refers to the resistance of a complex of two or more agents to dissociation after dilution.
• the terms “immunoreactive” and “preferentially binds” are used interchangeably herein with respect to antibodies and/or antigen-binding fragments.
• binding refers to a direct association between two molecules, due to, for example, covalent, electrostatic, hydrophobic, and ionic and/or hydrogen-bond interactions, including interactions such as salt bridges and water bridges.
• a subject anti-Cls antibody binds specifically to an epitope within a complement Cls protein.
• Specific binding refers to binding with an affinity of at least about 10 "7 M or greater, e.g., 5x 10 "7 M, 10 ⁇ 8 M, 5x l0 ⁇ 8 M, and greater.
• Non-specific binding refers to binding with an affinity of less than about 10 "7 M, e.g., binding with an affinity of 10 "6 M, 10 "5 M, 10 "4 M, etc.
• k 0 n is intended to refer to the rate constant for association of an antibody to an antigen.
• k 0 ff is intended to refer to the rate constant for dissociation of an antibody from the antibody/antigen complex.
• KD is intended to refer to the equilibrium dissociation constant of an antibody-antigen interaction.
• percent (%) amino acid sequence identity and “homology” with respect to a peptide, polypeptide or antibody sequence refers to the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or MEGALIGNTM (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms known in the art needed to achieve maximal alignment over the full length of the sequences being compared.
• a “biological sample” encompasses a variety of sample types obtained from an individual and can be used in a diagnostic or monitoring assay.
• the definition encompasses blood and other liquid samples of biological origin, solid tissue samples such as a biopsy specimen or tissue cultures or cells derived therefrom and the progeny thereof.
• the definition also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents, solubilization, or enrichment for certain components, such as polynucleotides.
• biological sample encompasses a clinical sample, and also includes cells in culture, cell supernatants, cell lysates, serum, plasma, biological fluid, and tissue samples.
• biological sample includes urine, saliva, cerebrospinal fluid, interstitial fluid, ocular fluid, synovial fluid, blood fractions such as plasma and serum, and the like.
• biological sample also includes solid tissue samples, tissue culture samples, and cellular samples.
• an "isolated" nucleic acid molecule is a nucleic acid molecule that is identified and separated from at least one contaminant nucleic acid molecule with which it is ordinarily associated in the environment in which it was produced. Preferably, the isolated nucleic acid is free of association with all components associated with the production environment.
• the isolated nucleic acid molecules encoding the polypeptides and antibodies herein is in a form other than in the form or setting in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from nucleic acids encoding any polypeptides and antibodies herein that exist naturally in cells.
• vector is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
• plasmid refers to a circular double stranded DNA into which additional DNA segments may be ligated.
• phage vector refers to a viral vector, wherein additional DNA segments may be ligated into the viral genome.
• viral vector is capable of autonomous replication in a host cell into which they are introduced ⁇ e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
• vectors ⁇ e.g., non-episomal mammalian vectors
• vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
• certain vectors are capable of directing the expression of genes to which they are operatively linked.
• Such vectors are referred to herein as "recombinant expression vectors," or simply, "expression vectors.”
• expression vectors useful in recombinant DNA techniques are often in the form of plasmids.
• plasmid and “vector” may be used interchangeably as the plasmid is the most commonly used form of vector.
• Polynucleotide or “nucleic acid” as used interchangeably herein, refer to polymers of nucleotides of any length, and include DNA and RNA.
• the nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and/or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase or by a synthetic reaction.
• a polynucleotide may comprise modified nucleotides, such as methylated nucleotides and their analogs. If present, modification to the nucleotide structure may be imparted before or after assembly of the polymer.
• the sequence of nucleotides may be interrupted by non-nucleotide components.
• a polynucleotide may comprise modification(s) made after synthesis, such as conjugation to a label.
• Other types of modifications include, for example, "caps,” substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, those with uncharged linkages ⁇ e.g. , methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) and with charged linkages ⁇ e.g.
• phosphorothioates those containing pendant moieties, such as, for example, proteins ⁇ e.g., nucleases, toxins, antibodies, signal peptides, ply-L-lysine, etc.), those with intercalators ⁇ e.g. , acridine, psoralen, etc.), those containing chelators ⁇ e.g. , metals, radioactive metals, boron, oxidative metals, etc.), those containing alkylators, those with modified linkages ⁇ e.g. , alpha anomeric nucleic acids, etc.), as well as unmodified forms of the polynucleotides(s).
• proteins ⁇ e.g., nucleases, toxins, antibodies, signal peptides, ply-L-lysine, etc.
• intercalators e.g. , acridine, psoralen, etc.
• those chelators ⁇ e.g. , metals
• any of the hydroxyl groups ordinarily present in the sugars may be replaced, for example, by phosphonate groups, phosphate groups, protected by standard protecting groups, or activated to prepare additional linkages to additional nucleotides, or may be conjugated to solid or semi-solid supports.
• the 5' and 3 ' terminal OH can be phosphorylated or substituted with amines or organic capping group moieties of from 1 to 20 carbon atoms.
• Other hydroxyls may also be derivatized to standard protecting groups.
• Polynucleotides can also contain analogous forms of ribose or deoxyribose sugars that are generally known in the art, including, for example, 2'-0-methyl-, 2'-0-allyl-, 2'-fluoro- or 2'-azido-ribose, carbocyclic sugar analogs, a-anomeric sugars, epimeric sugars such as arabinose, xyloses or lyxoses, pyranose sugars, furanose sugars, sedoheptuloses, acyclic analogs, and basic nucleoside analogs such as methyl riboside.
• One or more phosphodiester linkages may be replaced by alternative linking groups.
• linking groups include, but are not limited to, embodiments wherein phosphate is replaced by P(0)S ("thioate”), P(S)S ("dithioate”), (0)NR 2 ("amidate”), P(0)R, P(0)OR', CO, or CH 2 ("formacetal”), in which each R or R' is independently H or substituted or unsubstituted alkyl (1-20 C) optionally containing an ether (-0-) linkage, aryl, alkenyl, cycloalkyl, cycloalkenyl or aralkyl. Not all linkages in a polynucleotide need be identical. The preceding description applies to all polynucleotides referred to herein, including RNA and DNA.
• a "host DCr includes an individual cell or cell culture that can be or has been a recipient for vector(s) for incorporation of polynucleotide inserts.
• Host cells include progeny of a single host cell, and the progeny may not necessarily be completely identical (in morphology or in genomic DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation.
• a host cell includes cells transfected in vivo with a polynucleotide(s) of this disclosure.
• Carriers as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers that are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution.
• physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEENTM, polyethylene glycol (PEG), and PLURONICSTM.
• buffers such as phosphate, citrate, and other organic acids
• antioxidants including ascorbic acid
• proteins such as serum albumin,
• neurotrophins refers to neurotrophic factors that are neuroprotective in the brain. These factors are suitable for use in the compositions and methods of the disclosure and include brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-4/5, fibroblast growth factor (FGF)-2 and other FGFs, neurotrophin (NT)-3, erythropoietin (EPO), hepatocyte growth factor (HGF), epidermal growth factor (EGF), transforming growth factor (TGF)-a, TGF- ⁇ , vascular endothelial growth factor (VEGF), interleukin-1 receptor antagonist (IL-lra), ciliary neurotrophic factor (CNTF), glial-derived neurotrophic factor (GDNF), neurturin, platelet-derived growth factor (PDGF), heregulin, neuregulin, artemin, persephin, interleukins, granulocyte-colony stimulating factor (CSF), granulocyte-macrophage-CSF, net
• preventing is art-recognized, and when used in relation to a condition, such as an FTD disease, is well understood in the art, and includes administration of a composition which reduces the frequency or severity, or delays the onset, of one or more symptoms of the medical condition in a subject relative to a subject who does not receive the composition.
• the prevention of FTD disease progression includes, for example, slowing the average amount of neurodegeneration in a population of patients receiving a therapy relative to a control population that did not receive the therapy, e.g., by a statistically and/or clinically significant amount.
• the prevention of neurodegenerative disease progression includes reducing the likelihood that a patient receiving a therapy will develop a disability, such as cognitive decline and/or memory loss, or delaying the onset of disability, relative to a patient who does not receive the therapy.
• subject refers to a living mammal and may be
• mammals include, but are not limited to, any member of the mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
• the term does not denote a particular age or gender.
• treating includes reducing, arresting, or reversing the symptoms, clinical signs, or underlying pathology of a condition to stabilize or improve a subject's condition or to reduce the likelihood that the subject's condition will worsen as much as if the subject did not receive the treatment.
• terapéuticaally effective amount' of a compound with respect to the subject method of treatment refers to an amount of the compound(s) in a preparation which, when administered as part of a desired dosage regimen (to a mammal, preferably a human) alleviates a symptom, ameliorates a condition, or slows the onset of disease conditions according to clinically acceptable standards for the disorder or condition to be treated or the cosmetic purpose, e.g., at a reasonable benefit/risk ratio applicable to any medical treatment.
• a therapeutically effective amount herein may vary according to factors such as the disease state, age, sex, and weight of the patient, and the ability of the antibody to elicit a desired response in the individual.
• an individual “at risk”' of developing a particular disease, disorder, or condition may or may not have detectable disease or symptoms of disease, and may or may not have displayed detectable disease or symptoms of disease prior to the treatment methods described herein.
• At risk denotes that an individual has one or more risk factors, which are measurable parameters that correlate with development of a particular disease, disorder, or condition, as known in the art. An individual having one or more of these risk factors has a higher probability of developing a particular disease, disorder, or condition than an individual without one or more of these risk factors.
• Chronic administration refers to administration of the medicament(s) in a continuous as opposed to acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time.
• Intermittent' administration refers to treatment that is not administered consecutively without interruption, but rather is cyclic/periodic in nature.
• administration includes simultaneous administration and/or administration at different times. Conjoint administration also encompasses administration as a co-formulation or administration as separate compositions, including at different dosing frequencies or intervals, and using the same route of administration or different routes of administration.
• Antibodies suitable for use in the methods of the present disclosure may be produced using recombinant methods and compositions, e.g., as described in U.S. Patent No.
• isolated nucleic acids having a nucleotide sequence encoding any of the antibodies of the present disclosure are provided. Such nucleic acids may encode an amino acid sequence containing the VL/CL and/or an amino acid sequence containing the VH/CH1 of the anti-Clq, anti-Clr or anti-Cls antibody.
• one or more vectors ⁇ e.g., expression vectors) containing such nucleic acids are provided. A host cell containing such nucleic acid may also be provided.
• the host cell may contain ⁇ e.g., has been transduced with): (1) a vector containing a nucleic acid that encodes an amino acid sequence containing the VL/CL of the antibody and an amino acid sequence containing the VH/CH1 of the antibody, or (2) a first vector containing a nucleic acid that encodes an amino acid sequence containing the VL/CL of the antibody and a second vector containing a nucleic acid that encodes an amino acid sequence containing the VH/CH1 of the antibody.
• the host cell is eukaryotic, e.g., a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell).
• the method includes culturing a host cell of the present disclosure containing a nucleic acid encoding the anti-Clq, anti-Clr or anti-C l s antibody, under conditions suitable for expression of the antibody.
• the antibody is subsequently recovered from the host cell (or host cell culture medium).
• a nucleic acid encoding the antibody is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell.
• Such nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
• Suitable vectors containing a nucleic acid sequence encoding any of the antibodies of the present disclosure, or fragments thereof polypeptides (including antibodies) described herein include, without limitation, cloning vectors and expression vectors.
• Suitable cloning vectors can be constructed according to standard techniques, or may be selected from a large number of cloning vectors available in the art. While the cloning vector selected may vary according to the host cell intended to be used, useful cloning vectors generally have the ability to self-replicate, may possess a single target for a particular restriction endonuclease, and/or may carry genes for a marker that can be used in selecting clones containing the vector.
• Suitable examples include plasmids and bacterial viruses, e.g., pUC18, pUC19, Bluescript (e.g., pBS SK+) and its derivatives, mpl8, mpl9, pBR322, pMB9, ColEl, pCRl, RP4, phage DNAs, and shuttle vectors such as pSA3 and pAT28.
• Bluescript e.g., pBS SK+
• mpl8 mpl9 mpl9
• pBR322 mpl9
• ColEl ColEl
• pCRl pCRl
• RP4 phage DNAs
• shuttle vectors such as pSA3 and pAT28.
• the vectors containing the nucleic acids of interest can be introduced into the host cell by any of a number of appropriate means, including electroporation, transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; and infection (e.g., where the vector is an infectious agent such as vaccinia virus).
• electroporation employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances
• microprojectile bombardment e.g., where the vector is an infectious agent such as vaccinia virus.
• infection e.g., where the vector is an infectious agent such as vaccinia virus.
• the vector contains a nucleic acid containing one or more amino acid sequences encoding an anti- Clq, anti-C lr or anti-Cl s antibody of the present disclosure.
• Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells.
• an anti-Clq, anti-Clr or anti-C l s antibody of the present disclosure may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed.
• For expression of antibody fragments and polypeptides in bacteria e.g., U.S. Patent Nos. 5,648,237, 5,789, 199, and 5,840,523; and Charlton, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245- 254, describing expression of antibody fragments in E. coli).
• the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
• Candidate antibodies can be screened for the ability to modulate synapse loss. Such screening may be performed using an in vitro model, a genetically altered cell or animal, or purified protein. A wide variety of assays may be used for this purpose, such as an in vitro culture system.
• an in vitro culture system may include the addition of microglial cells to cultures of cortical neurons, followed by counting the number of synapses removed from the neurons and/or ingested by the microglial cells.
• Functional activity of a candidate antibody may also be tested in vivo by assessing the ability of the antibody to modulate synapse loss during normal aging, e.g., in animals challenged with intracerebral injection of amyloid-beta oligomers, or in animals genetically modified with human familial mutations associated with FTD or in animals with induced forms of FTD.
• Candidate antibodies may also be identified using computer-based modeling, by binding assays, and the like. Various in vitro models may be used to determine whether an antibody binds to, or otherwise affects complement activity. Such candidate antibodies may be tested by contacting neurons in an environment permissive for synapse loss. Such antibodies may be further tested in an in vivo model for an effect on synapse loss.
• Synapse loss may be quantitated by administering the candidate antibodies to neurons in culture, and determining the presence of synapses in the absence or presence of the antibodies.
• the neurons are a primary culture, e.g., of retinal ganglion cells (RGCs). Purified populations of RGCs are obtained by conventional methods, such as sequential immunopanning.
• the cells are cultured in suitable medium, which will usually comprise appropriate growth factors, e.g., CNTF; BDNF; etc.
• the neural cells e.g., RCGs, are cultured for a period of time sufficient allow robust process outgrowth and then cultured with a candidate antibodies for a period of about 1 day to 1 week.
• the neurons may be cultured on a live astrocyte cell feeder in order to induce signaling for synapse loss.
• Methods of culturing astrocyte feeder layers are known in the art.
• cortical glia can be plated in a medium that does not allow neurons to survive, with removal of non-adherent cells.
• cultures are fixed, blocked and washed, then stained with an antibody specific for synaptic proteins, e.g., synaptotagmin, etc. and visualized with an appropriate reagent. Analysis of the staining may be performed microscopically.
• digital images of the fluorescence emission are with a camera and image capture software, adjusted to remove unused portions of the pixel value range and the used pixel values adjusted to utilize the entire pixel value range.
• Corresponding channel images may be merged to create a color (RGB) image containing the two single-channel images as individual color channels.
• Co-localized puncta can be identified using a rolling ball background subtraction algorithm to remove low-frequency background from each image channel. Number, mean area, mean minimum and maximum pixel intensities, and mean pixel intensities for all synaptotagmin, PSD-95, and colocalized puncta in the image are recorded for analysis.
• a plurality of assay mixtures are run in parallel with different antibody concentrations to obtain a differential response to the various concentrations.
• one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.
• An antibody of the present disclosure may be administered in the form of
• Therapeutic formulations of an antibody of the disclosure may be prepared for storage by mixing the antibody having the desired degree of purity with optional pharmaceutically acceptable carriers, excipients or stabilizers ⁇ Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. [1980]), in the form of lyophilized formulations or aqueous solutions.
• Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine,
• chelating agents such as EDTA
• sugars such as sucrose, mannitol, trehalose or sorbitol
• salt-forming counter-ions such as sodium
• metal complexes e.g., Zn-protein complexes
• non-ionic surfactants such as TWEENTM, PLURONICSTM or
• PEG polyethylene glycol
• Lipofections or liposomes may also be used to deliver an antibody or antibody fragment into a cell, wherein the epitope or smallest fragment which specifically binds to the binding domain of the target protein is preferred.
• the antibody may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example,
• microcapsules respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in
• the formulations to be used for parenteral administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.
• Sustained-release preparations may be prepared. Suitable examples of sustained- release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No.
• copolymers of L-glutamic acid and ⁇ ethyl -L-glutamate non-degradable ethylene-vinyl acetate
• degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOTTM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate)
• poly-D-(-)-3-hydroxybutyric acid While polymers such as ethylene- vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
• the antibodies and compositions of the present disclosure are typically administered by various routes, including, but not limited to, topical, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intranasal, and intralesional administration.
• Parenteral routes of administration include intramuscular, intravenous, intra-arterial, intraperitoneal, intrathecal, or subcutaneous administration.
• compositions may also include, depending on the formulation desired, pharmaceutically-acceptable, non-toxic carriers of diluents, which are defined as vehicles commonly used to formulate pharmaceutical compositions for animal or human
• the diluent is selected so as not to affect the biological activity of the combination.
• examples of such diluents are distilled water, buffered water, physiological saline, PBS, Ringer's solution, dextrose solution, and Hank's solution.
• the pharmaceutical composition or formulation may include other carriers, adjuvants, or non- toxic, nontherapeutic, non-immunogenic stabilizers, excipients and the like.
• compositions may also include additional substances to approximate physiological conditions, such as pH adjusting and buffering agents, toxicity adjusting agents, wetting agents and detergents.
• the composition may also include any of a variety of stabilizing agents, such as an antioxidant for example.
• the polypeptide may be complexed with various well-known compounds that enhance the in vivo stability of the polypeptide, or otherwise enhance its pharmacological properties ⁇ e.g., increase the half-life of the polypeptide, reduce its toxicity, enhance other pharmacokinetic and/or pharmacodynamic characteristics, or enhance solubility or uptake). Examples of such modifications or complexing agents include sulfate, gluconate, citrate and phosphate.
• the polypeptides of a composition may also be complexed with molecules that enhance their in vivo attributes.
• Such molecules include, for example, carbohydrates, polyamines, amino acids, other peptides, ions ⁇ e.g., sodium, potassium, calcium, magnesium, manganese), and lipids. Further guidance regarding formulations that are suitable for various types of administration may be found in Remington's Pharmaceutical Sciences, Mace Publishing
• Toxicity and therapeutic efficacy of the active ingredient may be determined according to standard pharmaceutical procedures in cell cultures and/or experimental animals, including, for example, determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
• the dose ratio between toxic and therapeutic effects is the therapeutic index and it may be expressed as the ratio LD50/ED50.
• Compounds that exhibit large therapeutic indices are preferred.
• the data obtained from cell culture and/or animal studies may be used in formulating a range of dosages for humans.
• the dosage of the active ingredient typically lines within a range of circulating concentrations that include the ED50 with low toxicity.
• the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
• compositions described herein may be administered in a variety of different ways. Examples include administering a composition containing a
• pharmaceutically acceptable carrier via oral, intranasal, rectal, topical, intraperitoneal, intravenous, intramuscular, subcutaneous, subdermal, transdermal, intrathecal, and intracranial methods.
• the active ingredient may be administered in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions.
• the active component(s) may be encapsulated in gelatin capsules together with inactive ingredients and powdered carriers, such as glucose, lactose, sucrose, mannitol, starch, cellulose or cellulose derivatives, magnesium stearate, stearic acid, sodium saccharin, talcum, magnesium carbonate.
• additional inactive ingredients that may be added to provide desirable color, taste, stability, buffering capacity, dispersion or other known desirable features are red iron oxide, silica gel, sodium lauryl sulfate, titanium dioxide, and edible white ink. Similar diluents may be used to make compressed tablets. Both tablets and capsules may be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets may be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the
• Liquid dosage forms for oral administration may contain coloring and flavoring to increase patient acceptance.
• Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which may contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that may include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
• the components used to formulate the pharmaceutical compositions are preferably of high purity and are substantially free of potentially harmful contaminants (e.g., at least National Food (NF) grade, generally at least analytical grade, and more typically at least pharmaceutical grade).
• compositions intended for parenteral use are usually sterile.
• compositions for parental administration are also typically substantially isotonic and made under GMP conditions.
• compositions of the disclosure may be administered using any medically appropriate procedure, e.g., intravascular (intravenous, intraarterial, intracapillary) administration, injection into the cerebrospinal fluid, intravitreal, topical, intracavity or direct injection in the brain.
• Intrathecal administration may be carried out through the use of an Ommaya reservoir, in accordance with known techniques. (F. Balis et al., Am J. Pediatr. Hematol. Oncol. 11, 74, 76 (1989).
• one method for administration of the therapeutic compositions of the disclosure is by deposition into or near the site by any suitable technique, such as by direct injection (aided by stereotaxic
• a convection-enhanced delivery catheter may be implanted directly into the site, into a natural or surgically created cyst, or into the normal brain mass.
• Such convection-enhanced pharmaceutical composition delivery devices greatly improve the diffusion of the composition throughout the brain mass.
• the implanted catheters of these delivery devices utilize high-flow microinfusion (with flow rates in the range of about 0.5 to 15.0 ⁇ /minute), rather than diffusive flow, to deliver the therapeutic composition to the brain and/or tumor mass.
• the effective amount of a therapeutic composition given to a particular patient may depend on a variety of factors, several of which may be different from patient to patient.
• a competent clinician will be able to determine an effective amount of a therapeutic agent to administer to a patient. Dosage of the agent will depend on the treatment, route of
• compositions may be administered to the subject in a series of more than one administration. For therapeutic compositions, regular periodic administration will sometimes be required, or may be desirable.
• Therapeutic regimens will vary with the agent; for example, some agents may be taken for extended periods of time on a daily or semi-daily basis, while more selective agents may be
• Formulations may be optimized for retention and stabilization in the brain.
• the agent When the agent is administered into the cranial compartment, it is desirable for the agent to be retained in the compartment, and not to diffuse or otherwise cross the blood brain barrier.
• Stabilization techniques include cross-linking, multimerizing, or linking to groups such as polyethylene glycol, polyacrylamide, neutral protein carriers, etc., in order to achieve an increase in molecular weight.
• Implants may be particles, sheets, patches, plaques, fibers, microcapsules and the like and may be of any size or shape compatible with the selected site of insertion.
• the implants may be monolithic, i.e., having the active agent homogenously distributed through the polymeric matrix, or encapsulated, where a reservoir of active agent is encapsulated by the polymeric matrix.
• the selection of the polymeric composition to be employed will vary with the site of administration, the desired period of treatment, patient tolerance, the nature of the disease to be treated and the like. Characteristics of the polymers will include biodegradability at the site of implantation, compatibility with the agent of interest, ease of encapsulation, a half-life in the physiological environment.
• Biodegradable polymeric compositions which may be employed may be organic esters or ethers, which when degraded result in physiologically acceptable degradation products, including the monomers.
• the polymers may be condensation polymers.
• the polymers may be cross-linked or non-cross-linked.
• Of particular interest are polymers of hydroxyaliphatic carboxylic acids, either homo- or copolymers, and
• polysaccharides Included among the polyesters of interest are polymers of D-lactic acid, L- lactic acid, racemic lactic acid, glycolic acid, polycaprolactone, and combinations thereof.
• L-lactate or D-lactate a slowly biodegrading polymer is achieved, while degradation is substantially enhanced with the racemate.
• Copolymers of glycolic and lactic acid are of particular interest, where the rate of biodegradation is controlled by the ratio of glycolic to lactic acid. The most rapidly degraded copolymer has roughly equal amounts of glycolic and lactic acid, where either homopolymer is more resistant to degradation.
• the ratio of glycolic acid to lactic acid will also affect the brittleness of in the implant, where a more flexible implant is desirable for larger geometries.
• polysaccharides of interest are calcium alginate, and functionalized celluloses, particularly carboxymethylcellulose esters characterized by being water insoluble, a molecular weight of about 5 kD to 500 kD, etc.
• Biodegradable hydrogels may also be employed in the implants of the subject disclosure. Hydrogels are typically a copolymer material, characterized by the ability to imbibe a liquid. Exemplary biodegradable hydrogels which may be employed are described in Heller in: Hydrogels in Medicine and Pharmacy, N. A. Peppes ed., Vol. Ill, CRC Press, Boca Raton, Fla., 1987, pp 137-149.
• the present disclosure also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical
• compositions Associated with such container(s) may be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.
• Kits of the present disclosure may include one or more containers comprising a purified anti-Clq, anti-Clr or anti-Cls antibody and instructions for use in accordance with methods known in the art.
• these instructions comprise a description of administration of the inhibitor to treat or diagnose a disease, according to any methods known in the art.
• the kit may further comprise a description of selecting an individual suitable for treatment based on identifying whether that individual has FTD and the stage of the FTD.
• the instructions generally include information as to dosage, dosing schedule, and route of administration for the intended treatment.
• the containers may be unit doses, bulk packages (e.g., multi-dose packages) or sub-unit doses.
• Instructions supplied in the kits of the present disclosure are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit), but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.
• the label or package insert indicates that the composition is used for treating FTD. Instructions may be provided for practicing any of the methods described herein.
• kits of this disclosure are preferably disposed in suitable packaging.
• suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags), and the like.
• packages for use in combination with a specific device such as an inhaler, nasal administration device (e.g., an atomizer) or an infusion device such as a minipump.
• a kit may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
• the container may also have a sterile access port (e.g., the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an inhibitor of classical complement pathway.
• the container may further comprise a second
• Kits may optionally provide additional components such as buffers and interpretive information.
• the kit comprises a container and a label or package insert(s) on or associated with the container.
• a number of molecules are known that inhibit the activity of complement.
• suitable inhibitors can be screened by methods described herein.
• normal cells can produce proteins that block complement activity, e.g., CD59, CI inhibitor, etc.
• complement is inhibited by upregulating expression of genes encoding such polypeptides.
• Modifications of molecules that block complement activation are also known in the art.
• such molecules include, without limitation, modified complement receptors, such as soluble CR1.
• modified complement receptors such as soluble CR1.
• the mature protein of the most common allotype of CR1 contains 1998 amino acid residues: an extracellular domain of 1930 residues, a transmembrane region of 25 residues, and a cytoplasmic domain of 43 residues.
• the entire extracellular domain is composed of 30 repeating units referred to as short consensus repeats (SCRs) or complement control protein repeats (CCPRs), each consisting of 60 to 70 amino acid residues.
• SCRs short consensus repeats
• CCPRs complement control protein repeats
• Clq binds specifically to human CR1.
• CR1 recognizes all three complement opsonins, namely C3b, C4b, and Clq.
• sCRl human CR1
• cClqR human Clq receptors
• Decay accelerating factor (DAF) (CD55) is composed of four SCRs plus a
• DAF serine/threonine-enriched domain that is capable of extensive O-linked glycosylation.
• DAF is attached to cell membranes by a glycosyl phosphatidyl inositol (GPI) anchor and, through its ability to bind C4b and C3b, it acts by dissociating the C3 and C5 convertases.
• GPI glycosyl phosphatidyl inositol
• CI inhibitor a member of the "serpin" family of serine protease inhibitors, is a heavily glycosylated plasma protein that prevents fluid-phase CI activation.
• CI inhibitor regulates the classical pathway of complement activation by blocking the active site of Clr and Cls and dissociating them from Clq.
• Peptide inhibitors of complement activation include C5a and other inhibitory molecules include Fucan.
• Synapse loss are asymmetric communication junctions formed between two neurons, or, at the neuromuscular junction (NMJ) between a neuron and a muscle cell. Chemical synapses enable cell-to-cell communication via secretion of neurotransmitters, whereas in electrical synapses signals are transmitted through gap junctions, specialized intercellular channels that permit ionic current flow. In addition to ions, other molecules that modulate synaptic function (such as ATP and second messenger molecules) can diffuse through gap junctional pores.
• pre- and postsynaptic membranes are separated by a synaptic cleft containing extracellular proteins that form the basal lamina. Synaptic vesicles are clustered at the presynaptic release site, transmitter receptors are clustered in junctional folds at the postsynaptic membrane, and glial processes surround the nerve terminal.
• Synaptogenesis is a dynamic process. During development, more synapses are typically established than ultimately will be retained. Therefore, the elimination of excess synaptic inputs is a critical step in synaptic circuit maturation. Synapse elimination is a competitive process that involves interactions between pre- and postsynaptic partners. In the CNS, as with the NMJ, a developmental, activity-dependent remodeling of synaptic circuits takes place by a process that may involve the selective stabilization of coactive inputs and the elimination of inputs with uncorrected activity. The anatomical refinement of synaptic circuits occurs at the level of individual axons and dendrites by a dynamic process that involves rapid elimination of synapses. As axons branch and remodel, synapses form and dismantle with synapse elimination occurring rapidly.
• synapse loss is an early pathological event common to many neurodegenerative disorders, including FTD, and is the best correlate to the cognitive impairment.
• AD pre-clinical Alzheimer's disease
• transgenic animal models have shown that synaptic damage occurs early in disease progression. This early disruption of synaptic connections in the brain results in neuronal dysfunction that, in turn, leads to the characteristic symptoms of dementia and/or motor impairment observed in several neurodegenerative disorders.
• ⁇ has a preferential localization at central and peripheral synaptic sites.
• abnormal expression of mutant forms of ⁇ results not only in amyloid deposition, but also in widespread synaptic damage. This synaptic pathology occurs early and is associated with levels of soluble ⁇ 1-42 rather than with plaque formation.
• Other neurodegenerative diseases where gene products have been shown to be closely associated with synaptic complexes include Huntington's disease (HD) and myotonic dystrophy (DM).
• Huntingtin (HTT) is a membrane-bound protein with a distribution very similar to that of synaptic vesicle protein synaptophysin.
• DMK serine/ threonine kinase
• Antibodies disclosed herein may be used to inhibit synapse loss. Inhibiting synapse loss results in maintenance of or reduced loss of synapses, where a decrease would otherwise occur.
• the "blood-brain barrier” refers to the barrier between the peripheral circulation and the brain and spinal cord.
• the BBB is formed by tight junctions within the brain capillary endothelial plasma membrane. The formation of such tight junctions creates an extremely tight barrier that restricts the transport of molecules into the brain, even molecules as small as urea, molecular weight of 60 Da.
• the blood-brain barrier within the brain, the blood-spinal cord barrier within the spinal cord, and the blood-retinal barrier within the retina are contiguous capillary barriers within the central nervous system (CNS), and are collectively referred to as the blood-brain barrier or BBB.
• compositions and methods that include an antibody that binds to a BBB receptor mediated transport system, coupled to an agent for which transport across the BBB is desired, e.g., a neurotherapeutic agent.
• the compositions and methods of the disclosure may utilize any suitable structure that is capable of transport by the selected endogenous BBB receptor- mediated transport system, and that is also capable of attachment to the desired agent.
• the BBB has been shown to have specific receptors that allow the transport from the blood to the brain of several macromolecules; these transporters are suitable as transporters for compositions of the disclosure.
• Endogenous BBB receptor-mediated transport systems useful in the disclosure include those that transport insulin, transferrin, insulin-like growth factors 1 and 2 (IGF1 and IGF2), leptin, and lipoproteins.
• the disclosure utilizes a structure that is capable of crossing the BBB via the endogenous insulin BBB receptor-mediated transport system, e.g., the human endogenous insulin BBB receptor- mediated transport system.
• BBB blood brain barrier
• osmotic means such as mannitol or leukotrienes
• vasoactive substances such as bradykinin.
• a BBB disrupting agent can be coadministered with the therapeutic compositions of the disclosure when the compositions are administered by intravascular injection.
• Other strategies to go through the BBB may entail the use of endogenous transport systems, including carrier-mediated transporters such as glucose and amino acid carriers, receptor-mediated transcytosis for insulin or transferrin, and active efflux transporters such as p-glycoprotein.
• Active transport moieties may also be conjugated to the antibodies of the disclosure to facilitate transport across the epithelial wall of the blood vessel.
• drug delivery behind the BBB may be pursued, e.g., by intrathecal delivery of agents directly to the cerebrospinal fluid, as through an Ommaya reservoir.
• the antibodies of the present disclosure may be useful in the present methods of preventing, reducing risk of developing, or treating FTD or a variant of FTD, comprising administering an inhibitor of the complement pathway ⁇ e.g., an inhibitor, such as an anti-Clq, -Clr, or -Cls antibody).
• an inhibitor of the complement pathway e.g., an inhibitor, such as an anti-Clq, -Clr, or -Cls antibody.
• the antibodies of the present disclosure may also be useful in inhibiting synapse loss in FTD.
• Synapse loss is a significant correlate of cognitive decline that serves as a critical hallmark of neurodegenerative diseases. For example, microglia prune developing synapses and regulate synaptic plasticity and function. Disruptions in microglia-synapse interactions contribute to synapse loss and dysfunction, including cognitive impairment in
• microglia such as complement proteins or complement and fractalkine receptors
• fractalkine receptors results in synaptic and wiring abnormalities in both prenatal and postnatal brain development implicating microglia in sculpting synaptic connectivity.
• Frontotemporal lobar degeneration may be used as a pathological term used for the description of a clinically, pathologically and genetically heterogeneous group of disorders in which selective degeneration of the frontal and temporal lobes is a prominent feature.
• the clinical term frontotemporal dementia is used for the description of early onset dementias. FTD may overlap with motor neuron disease/amyotrophic lateral sclerosis (MND/ALS) (FTD- MND), Corticobasal syndrome (CBS) and progressive palsy (PSP) syndrome.
• MND/ALS motor neuron disease/amyotrophic lateral sclerosis
• CBS Corticobasal syndrome
• PSP progressive palsy
• FTD is also a highly heritable disorder with approximately 30-50% of cases reporting positive family history, although an autosomal dominant history accounts for approximately 10% of the cases. Mutations in three genes, microtubule-associated protein tau (MAPT), progranulin (GRN) and chromosome 9 open reading frame 72 (C9orf72) genes are considered responsible for most of the familial cases, and about 10-20% of all cases with FTD.
• MTT microtubule-associated protein tau
• GNN progranulin
• C9orf72 chromosome 9 open reading frame 72
• Frontotemporal dementia may be classified into three clinical variants: behavioral- variant frontotemporal dementia, which is associated with early behavioral and executive deficits; non-fluent variant primary progressive aphasia, with progressive deficits in speech, grammar, and word output; and semantic- variant primary progressive aphasia, which is a progressive disorder of semantic knowledge and naming.
• Clinically FTD patients can present with one of three canonical clinical syndromes: behavioral variant FTD (bvFTD), and two language variants, semantic dementia and progression non-fluent aphasia (PNFA).
• bvFTD is associated with early behavioral and executive deficits, which refers to the higher-level cognitive skills that control and coordinate other cognitive abilities and behaviors.
• Semantic dementia also called semantic-variant primary progressive aphasia
• PNFA is typically characterized by progressive deficits in speech, grammar, and word aphasia.
• the symptoms of the three clinical variants may converge, such as when an initially focal degeneration becomes more diffuse and spreads to affect large regions in the frontal and temporal lobes.
• patients develop global cognitive impairment and motor deficits, including Parkinsonism, and motor neuron disease in some patients.
• Patents with end-stage disease generally have difficulty eating, moving, and swallowing. Death usually happens about 8 years after symptom onset and typically caused by pneumonia or other secondary infections.
• the most common pronounced early symptoms of behavioral variant frontotemporal dementia include personality changes, disinhibition, and apathy.
• Some individuals who meet diagnostic criteria for behavioral -variant frontotemporal dementia may have a very slow disease course (over decades) with slow progression of cognitive impairment and often normal MRI and PET studies. Their disease is classified as frontotemporal dementia phenocopy.
• Some of these individuals have a primary psychiatric disturbance such as bipolar disorder, Asperger's syndrome, or factitious disease, whereas others might have a slow sporadic or genetic form of frontotemporal dementia
• Patients with primary progressive aphasia typically have a progressive, insidious decline in linguistic skills during the initial phase of the disease.
• Language dysfunction is commonly one of the main symptoms for the first 2 years of the illness. Deficits include language production, object naming, syntax, or word comprehension, and are apparent during conversation or through speech and language assessment. Language deficit is commonly one of the main causes of impaired activities of daily living. Although the underlying cause is more often frontotemporal dementia, primary progressive aphasia can be associated with Alzheimer's disease.
• Symptoms of semantic-variant primary progressive aphasia may result from early asymmetrical degeneration of anterior temporal lobes and amygdala. Semantic loss causes anomia for people, places, and objects; word-finding difficulties; and impaired word comprehension. Left temporal lobe variant presents with mainly linguistic semantic loss (semantic-variant primary).
• motor neuron disease typically including upper motor neuron signs (hyperreflexia, extensor plantar response, spasticity), lower motor neuron signs (weakness, muscle atrophy, fasciculations), dysarthria, dysphagia, and pseudobulbar affect. Mild features of motor neuron disease can occur in up to 40% of patients with frontotemporal dementia. Among the frontotemporal dementia variants, motor neuron disease arises frequently in patients with behavioral -variant frontotemporal dementia and less often in patients with semantic-variant primary progressive aphasia or nonfluent variant primary progressive aphasia.
• Corticobasal syndrome is characterized by asymmetrical parkinsonism, sensory-motor cortical dysfunction, alien-limb syndrome, and dystonia.
• Progressive supranuclear palsy syndrome is characterized by vertical supranuclear palsy, decreased saccade velocity, and early postural instability with falls. Behavioral changes, including executive dysfunction, apathy, and impulsivity, are common.
• agents that inhibit complement activation By administering agents that inhibit complement activation, synapses can be maintained that would otherwise be lost.
• agents include an anti-Clq, anti-Clr, or anti- Cls antibody inhibitor.
• Other agents may include inhibitors that upregulate expression of native complement, or agents that down-regulate Clq, Clr or Cls synthesis in neurons, astrocytes, microglia, endothelial, or oligodendroglial cells, agents that block complement activation, agents that block the signal for complement activation, and the like.
• the methods promote improved maintenance of neuronal function in conditions associated with synapse loss.
• the maintenance of neural connections provides for functional improvement in neurodegenerative disease relative to untreated patients.
• the prevention of synapse loss may comprise at least a measurable improvement relative to a control lacking such treatment over the period of 1, 2, 3, 4, 5, 6 days or at least one week, for example at least a 10% improvement in the number of synapses, at least a 20% improvement, at least a 50% improvement, or more.
• the agents of the present disclosure may be administered at a dosage that decreases synapse loss while minimizing any side-effects. It is contemplated that compositions may be obtained and used under the guidance of a physician for in vivo use.
• the dosage of the therapeutic formulation may vary widely, depending upon the nature of the disease, the frequency of administration, the manner of administration, the clearance of the agent from the host, and the like.
• the effective amount of a therapeutic composition given to a particular patient may depend on a variety of factors, several of which may be different from patient to patient. Utilizing ordinary skill, the competent clinician will be able to tailor the dosage of a particular therapeutic or imaging composition in the course of routine clinical trials.
• Therapeutic agents e.g., inhibitors of complement, activators of gene expression, etc. can be incorporated into a variety of formulations for therapeutic administration by combination with appropriate pharmaceutically acceptable carriers or diluents, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols.
• administration of the compounds can be achieved in various ways, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intrathecal, nasal, intratracheal, etc., administration.
• the active agent may be systemic after administration or may be localized by the use of regional administration, intramural administration, or use of an implant that acts to retain the active dose at the site of implantation.
• the complement inhibitors of the present disclosure may be used, without limitation, conjointly with any additional treatment, such as immunosuppressive therapies, for treating FTD.
• the antibodies of this disclosure may be administered in combination with an inhibitor of the alternative pathway of complement activation.
• inhibitors may include, without limitation, factor B blocking antibodies, factor D blocking antibodies, soluble, membrane-bound, tagged or fusion-protein forms of CD59, DAF, CR1, CR2, Crry or Compstatin-like peptides that block the cleavage of C3, non-peptide C3aR antagonists such as SB 290157, Cobra venom factor or non-specific complement inhibitors such as nafamostat mesilate (FUTHAN; FUT-175), aprotinin, K-76 monocarboxylic acid (MX-1) and heparin ⁇ see, e.g., T.E. Mollnes & M. Kirschfink, Molecular Immunology 43 (2006) 107-121).
• the antibodies of this disclosure are administered in combination with an inhibitor of the interaction between the autoantibody and its
• inhibitors may include purified soluble forms of the autoantigen, or antigen mimetics such as peptide or RNA-derived mimotopes, including mimotopes of the AQP4 antigen.
• inhibitors may include blocking agents that recognize the autoantigen and prevent binding of the autoantibody without triggering the classical complement pathway.
• blocking agents may include, e.g., autoantigen-binding RNA aptamers or antibodies lacking functional Clq, Clr, or Cls binding sites in their Fc domains ⁇ e.g., Fab fragments or antibodies otherwise engineered not to bind Clq, Clr, or Cls).
• neural progenitors such as those found in fetal tissues, neural stem cells, embryonic stem cells or other cells and tissues contemplated for neural repair or augmentation.
• neural progenitors such as those found in fetal tissues, neural stem cells, embryonic stem cells or other cells and tissues contemplated for neural repair or augmentation.
• Neural stem and progenitor cells can participate in aspects of normal development, including migration along well-established migratory pathways to disseminated CNS regions, differentiation into multiple neural progenitors.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Immunology (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Molecular Biology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Genetics & Genomics (AREA)
• Public Health (AREA)
• Biochemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Epidemiology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=60992917

Family Applications (1)

Country Status (6)

Cited By (1)

Families Citing this family (6)

Family Cites Families (5)

• 2017
  • 2017-07-19 EP EP17831788.9A patent/EP3487531A4/de not_active Withdrawn
  • 2017-07-19 WO PCT/US2017/042846 patent/WO2018017711A1/en unknown
  • 2017-07-19 AU AU2017299579A patent/AU2017299579A1/en not_active Abandoned
  • 2017-07-19 CA CA3030872A patent/CA3030872A1/en not_active Abandoned
  • 2017-07-19 SG SG11201900123TA patent/SG11201900123TA/en unknown
• 2019
  • 2019-01-09 IL IL264167A patent/IL264167A/en unknown

Also Published As

Similar Documents

Legal Events